Neoplastic disease or syndrome
MONDO:0023370Either an isolated neoplasm or a syndrome with neoplasm as a major feature.
Also known as: neoplastic disease, neoplastic disorder
32686 clinical trials for this condition and its sub-types, 7 tagged with Neoplastic disease or syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Neoplastic disease or syndrome
-
Neoplasm 3,884 trials · 32,490 incl. sub-types
48 sub-types
- Cancer 2,537 trials · 27,459 incl. sub-types Sub-types →
- Epithelial neoplasm 22 trials · 15,048 incl. sub-types Sub-types →
- Neoplasm of thorax 19 trials · 8,429 incl. sub-types Sub-types →
- Digestive system neoplasm 262 trials · 7,563 incl. sub-types Sub-types →
- Hematopoietic and lymphoid system neoplasm 692 trials · 6,319 incl. sub-types Sub-types →
- Reproductive system neoplasm 0 trials · 4,651 incl. sub-types Sub-types →
- Respiratory tract neoplasm 32 trials · 4,437 incl. sub-types Sub-types →
- Endocrine gland neoplasm 8 trials · 3,332 incl. sub-types Sub-types →
- Nervous system neoplasm 8 trials · 2,580 incl. sub-types Sub-types →
- Connective tissue neoplasm 1 trial · 2,404 incl. sub-types Sub-types →
- Head and neck neoplasm 79 trials · 2,200 incl. sub-types Sub-types →
- Urinary system neoplasm 21 trials · 1,690 incl. sub-types Sub-types →
- Virus associated tumor 5 trials · 1,241 incl. sub-types Sub-types →
- Melanocytic neoplasm 2 trials · 1,100 incl. sub-types Sub-types →
- Skin neoplasm 168 trials · 990 incl. sub-types Sub-types →
- Connective and soft tissue neoplasm 10 trials · 824 incl. sub-types Sub-types →
- Benign neoplasm 13 trials · 690 incl. sub-types Sub-types →
- Childhood neoplasm 46 trials · 649 incl. sub-types Sub-types →
- Peritoneal neoplasm 63 trials · 522 incl. sub-types Sub-types →
- Embryonal neoplasm 9 trials · 462 incl. sub-types Sub-types →
- Mesenchymal cell neoplasm 0 trials · 351 incl. sub-types Sub-types →
- Cardiovascular neoplasm 0 trials · 277 incl. sub-types Sub-types →
- Mixed neoplasm 0 trials · 192 incl. sub-types Sub-types →
- Mesothelial neoplasm 2 trials · 179 incl. sub-types Sub-types →
- Germ cell tumor 57 trials · 125 incl. sub-types Sub-types →
- Retroperitoneal neoplasm 3 trials · 84 incl. sub-types Sub-types →
- Histiocytoma 0 trials · 49 incl. sub-types Sub-types →
- Pre-malignant neoplasm 2 trials · 43 incl. sub-types Sub-types →
- Spindle cell neoplasm 1 trial · 40 incl. sub-types Sub-types →
- RET fusion positive cancer 20 trials
- Giant cell tumor 1 trial · 20 incl. sub-types Sub-types →
- NTRK fusion positive cancer 19 trials
- Upper aerodigestive tract neoplasm 18 trials
- Cystic neoplasm 0 trials · 17 incl. sub-types Sub-types →
- Trophoblastic neoplasm 1 trial · 15 incl. sub-types Sub-types →
- Odontogenic cyst 11 trials · 12 incl. sub-types Sub-types →
- Erythroplakia 8 trials
- Epidural spinal canal neoplasm 3 trials · 5 incl. sub-types Sub-types →
- Hamartoma 1 trial · 5 incl. sub-types Sub-types →
- Thyroglossal duct cyst 3 trials Sub-types →
- Bronchial adenomas/carcinoids childhood 1 trial
- Phosphaturic mesenchymal tumor 1 trial
- Dermoid or epidermoid cyst of the central nervous system 0 trials
- Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia 0 trials
- Mesenchymoma 0 trials Sub-types →
- Nail tumor 0 trials Sub-types →
- Non-seminomatous lesion 0 trials
- Skeletal muscle neoplasm 0 trials Sub-types →
-
Secondary neoplasm 9 trials · 1,528 incl. sub-types
5 sub-types
- Metastatic neoplasm 218 trials · 1,410 incl. sub-types Sub-types →
- Secondary malignant neoplasm 27 trials · 1,289 incl. sub-types Sub-types →
- Richter transformation 88 trials
- Pancoast syndrome 1 trial
- Malignant spiradenoma 0 trials Sub-types →
-
Neoplastic syndrome 1 trial · 1,430 incl. sub-types
11 sub-types
- Hereditary neoplastic syndrome 60 trials · 731 incl. sub-types Sub-types →
- Myelodysplastic syndrome 653 trials · 671 incl. sub-types Sub-types →
- Ectopic ACTH secretion syndrome 15 trials
- Autoimmune lymphoproliferative syndrome 11 trials · 12 incl. sub-types Sub-types →
- Ectopic hormone secretion syndrome associated with neoplasia 0 trials · 5 incl. sub-types Sub-types →
- Tumor lysis syndrome 3 trials
- Zollinger-Ellison syndrome 2 trials
- Pancoast syndrome 1 trial
- Carney triad 0 trials
- Meigs syndrome 0 trials
- Growing teratoma syndrome 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 7583 trials in this tab.
-
Rewriting the code: a One-Time gene fix for a rare immune disease?
Cure By invitation onlyThis trial tests a one-time gene therapy for WHIM syndrome, a rare inherited immune disorder that causes severe infections. Doctors collect a person's own blood stem cells, use base editing to correct the faulty CXCR4 gene, and return the edited cells to the body. The goal is to …
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Sep 20, 2026 00:00 UTC
-
Engineered immune cells target CS1 to fight stubborn myeloma
Cure OngoingResearchers are testing a new type of immune cell therapy called CS1-targeted CAR-T in adults with multiple myeloma that has come back or stopped responding to treatment. The study enrolls about 10 participants who have already received several lines of therapy. Doctors collect a…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Cure
Last updated Sep 20, 2026 00:00 UTC
-
Custom-Built immune cells take aim at a notorious cancer mutation
Cure OngoingResearchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Can a One-Two radiation punch improve prostate cancer control?
Cure OngoingResearchers are testing a combination of two radiation techniques for men with intermediate or high risk prostate cancer. Participants receive a shortened course of external beam radiation followed by a single high-dose brachytherapy boost, with optional hormone therapy. The tria…
Phase 1/2 • Sponsor: German Oncology Center, Cyprus • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Targeted radiation aims to cure prostate cancer while sparing healthy tissue
Cure By invitation onlyResearchers in Denmark are testing a targeted radiation technique called focal brachytherapy for men with early prostate cancer. The treatment places radioactive sources directly into the tumor, guided by MRI and ultrasound, to destroy cancer while leaving the rest of the prostat…
Sponsor: Herlev Hospital • Aim: Cure
Last updated Sep 18, 2026 00:00 UTC
-
Immunotherapy before surgery tested against aggressive skin cancer
Cure OngoingResearchers are testing whether giving the immunotherapy drug cemiplimab before and after surgery can help patients with high-risk cutaneous squamous cell carcinoma, a type of skin cancer. The trial enrolls people whose cancer has features that raise the risk of it coming back, s…
Phase 1 • Sponsor: Emory University • Aim: Cure
Last updated Sep 16, 2026 00:00 UTC
-
Can immunotherapy alone eliminate stomach tumors and spare patients surgery?
Cure OngoingResearchers are testing whether a combination of two immunotherapy drugs, tremelimumab and durvalumab, can treat MSI-high gastric or gastroesophageal junction cancer without immediate surgery. The trial enrolls adults with resectable tumors and gives the drugs before a planned op…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Cure
Last updated Sep 13, 2026 00:00 UTC
-
Robotic surgery aims to remove prostate through the perineum
Cure CancelledResearchers are testing a robotic approach to remove the prostate through the perineum, the area between the scrotum and anus, in men with localized prostate cancer. The study aims to see if the procedure can be completed safely and effectively using the GelPOINT device and a rob…
Sponsor: Chinese University of Hong Kong • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Can a calming drug make cord blood transplants safer?
Cure PausedResearchers are testing whether adding abatacept to standard immune-suppressing drugs can prevent severe graft-versus-host disease after a double umbilical cord blood transplant. The trial enrolls people with blood cancers such as leukemia, lymphoma, and myelodysplastic syndromes…
Phase 2 • Sponsor: Leland Metheny • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Engineered immune cells target CD70 in kidney cancer
Cure OngoingResearchers are testing a new cell therapy called ADI-270 in adults with clear cell renal cell carcinoma that has come back or stopped responding to standard treatments. ADI-270 uses engineered gamma-delta T cells that carry a chimeric receptor to seek out and attack cancer cells…
Phase 1/2 • Sponsor: Adicet Therapeutics • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
-
Can a Four-Part combo before surgery wipe out head and neck tumors?
Cure OngoingResearchers are testing whether giving low-dose radiotherapy, the immunotherapy drug tislelizumab, and two chemotherapy drugs before surgery helps people with locally advanced head and neck squamous cell carcinoma. The trial enrolls adults with untreated, operable stage III to IV…
Phase 2 • Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
New vaccine aimed at training immune system to fight advanced breast cancer enters first human tests
Vaccine OngoingThis early-stage trial tests a new vaccine called ES2B-C001, with or without an immune booster (adjuvant), in 40 people with HER2-positive metastatic breast cancer who have already tried other treatments. The vaccine is designed to help the body's immune system recognize and atta…
Phase 1 • Sponsor: ExpreS2ion Biotechnologies • Aim: Vaccine
Last updated Sep 20, 2026 00:00 UTC
-
New vaccine strategy could shield lymphoma survivors from pneumonia
Vaccine OngoingThis study looks at how well a pneumonia vaccine (PCV20) works in people who have recovered from B-cell lymphoma and were treated with anti-CD20 therapy. Researchers want to see if a single dose or a boosted dose is safer and more effective at preventing pneumococcal infections. …
Phase 4 • Sponsor: M.D. Anderson Cancer Center • Aim: Vaccine
Last updated Sep 17, 2026 00:00 UTC
-
New cocktail of drugs aimed at halting bone metastases in prostate cancer
Disease control PausedThis study tests a combination of three drugs—radium-223, M3814, and avelumab—in men with advanced prostate cancer that no longer responds to hormone therapy and has spread to the bone. The goal is to see if the combination can slow cancer growth better than radium-223 alone. The…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Breast cancer drug ribociclib made available Long-Term in new study
Disease control OngoingThis study offers continued access to the targeted cancer drug ribociclib for people with metastatic breast cancer who are already benefiting from it in a previous Novartis trial. About 134 participants will keep taking ribociclib, sometimes with other hormone therapies, while re…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Hope for early breast cancer: targeted drug may cut recurrence risk
Disease control OngoingThis phase 3 trial tests whether adding the targeted drug ribociclib to standard hormone therapy can help prevent breast cancer from coming back in people with early-stage, hormone receptor-positive, HER2-negative breast cancer. Over 5,000 participants are randomly assigned to re…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New mRNA vaccine combo aims to stop lung cancer recurrence
Disease control OngoingThis Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug duo targets Hard-to-Treat lymphomas
Disease control OngoingThis early-stage trial tests the safety and best dose of combining two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The study includes about 48 adults with various types of non-Hodgkin lymphoma. Resea…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo targets genetic weakness in advanced breast cancer
Disease control OngoingThis study tests a combination of two drugs—alpelisib (a targeted therapy) and fulvestrant (a hormone blocker)—in Japanese men and postmenopausal women with a specific type of advanced breast cancer (HR+/HER2-) that has a PIK3CA mutation. The cancer must have worsened after prior…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a single dose of radiation during surgery improve pancreatic cancer outcomes?
Disease control OngoingThis trial is testing whether giving a single dose of radiation directly to the tumor area during surgery is safe for people with localized pancreatic cancer. Participants first receive standard chemotherapy and stereotactic body radiation therapy (SBRT), then at the time of surg…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat myeloma
Disease control PausedThis study tests two oral drugs, mirdametinib and sirolimus, in people with relapsed or refractory multiple myeloma that has specific RAS gene mutations. The trial has two phases: first to find a safe dose, then to see how well the combo works. Up to 54 adults will take the drugs…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail takes on glioblastoma in early trial
Disease control OngoingThis early-stage study tests whether adding an experimental drug called OKN-007 to standard chemoradiotherapy is safe and tolerable for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 27 participants will receive the combination after surgery. The mai…
Phase 1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New Three-Drug cocktail aims to tackle tough lymphomas
Disease control OngoingThis study tests a new combination of three drugs—ALX148, lenalidomide, and rituximab—in people with B-cell non-Hodgkin lymphoma that has come back or not responded to treatment. The goal is to find the best dose and see how well the combo works at shrinking or eliminating tumors…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug JSB462 tested for advanced prostate cancer in japanese patients
Disease control OngoingThis early-stage study tests a new drug called JSB462 (Luxdegalutamide) in 15 Japanese men whose prostate cancer has spread to other parts of the body. The main goal is to check the drug's safety and how the body processes it. Participants take the drug once daily with food.
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New triple therapy aims to halt advanced breast cancer
Disease control OngoingThis study tests a combination of two experimental drugs (LEE011 and BYL719) plus a standard hormone therapy (letrozole) in about 255 women with advanced ER+ breast cancer. The goal is to find safe doses and see if the triple combination can better control the cancer. Participant…
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental vaccine aims to stop lung cancer from coming back
Disease control PausedThis trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remain…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat gut tumors
Disease control OngoingThis early-phase trial tests whether adding triapine to standard radioactive therapy (lutetium Lu 177 dotatate) is safe and effective for people with advanced neuroendocrine tumors of the digestive system. About 31 participants whose tumors have worsened after prior treatment wil…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat lung cancer
Disease control PausedThis early-phase trial is testing whether combining two drugs—vismodegib and atezolizumab—is safe and tolerable for people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer cells grow, while atezolizumab helps…
Phase 1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat carcinoid tumors
Disease control OngoingThis Phase II trial tests whether combining lenvatinib and everolimus can shrink or slow advanced carcinoid tumors that cannot be removed by surgery. The study enrolls 36 adults with confirmed unresectable carcinoid tumors. Both drugs are taken orally and work by blocking enzymes…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
One patient keeps receiving experimental colorectal cancer drug pair
Disease control Expanded access (ended)This expanded access program provides continued treatment with CA102N plus lonsurf to a single patient with advanced or metastatic colorectal cancer. The patient had already completed at least 12 cycles of the same combination in an earlier clinical study. Expanded access allows …
Sponsor: Holy Stone Healthcare Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immunotherapy combo shows promise in preventing High-Risk uterine cancer return
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without radiation) after surgery can help prevent high-risk endometrial cancer from coming back. About 990 participants who had surgery to remove their uterus and ovaries will r…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for seniors with aggressive blood cancer: targeted combo shows promise
Disease control OngoingThis study tests whether adding a targeted drug called polatuzumab vedotin to a standard chemotherapy regimen (R-miniCHP) can help people aged 75 and older with a type of lymphoma called DLBCL. The goal is to see if the combination improves how long patients live without their ca…
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a powerful drug cocktail halt multiple myeloma before it starts?
Disease control OngoingThis phase 2 trial tests a combination of three drugs—daratumumab, carfilzomib, and dexamethasone (DKd)—in people with high-risk smoldering multiple myeloma, a pre-cancer condition. The goal is to see if this treatment can prevent or delay the disease from turning into active mul…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can adding surgery or radiation to immunotherapy boost survival in advanced lung cancer?
Disease control OngoingThis study tests whether adding local treatments like surgery or radiation to a combination of two immunotherapy drugs (nivolumab and ipilimumab) helps people with stage IV non-small cell lung cancer live longer compared to immunotherapy alone. About 339 participants who have not…
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cocktail aims to knock out tough lymphoma
Disease control OngoingThis early-phase trial is testing whether adding the targeted drug polatuzumab vedotin (with or without another drug called glofitamab) to standard chemotherapy is safe for people with untreated, aggressive B-cell lymphoma. About 56 participants will receive the combination to se…
Phase 1 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Radioactive Bone-Seeking drug paired with chemo shows promise for advanced breast cancer
Disease control OngoingThis study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can an AI eye guide surgeons to safer, faster cancer removal?
Disease control OngoingThis trial tests an artificial intelligence system called ADTPS that helps doctors remove early-stage esophageal cancer or precancerous lesions using a scope. The AI analyzes live images during the procedure and overlays a suggested cutting path on the screen. Half of the partici…
Sponsor: Qilu Hospital of Shandong University • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Inhaled drug combo aims to boost lung cancer treatment before surgery
Disease control PausedThis study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a hyaluronic acid drug combo outperform bevacizumab in Hard-to-Treat colon cancer?
Disease control PausedResearchers are testing whether adding an experimental drug called CA102N to the chemotherapy TAS-102 helps control metastatic colorectal cancer better than adding bevacizumab to TAS-102. The trial enrolls about 100 adults whose cancer has grown after standard chemotherapy. Parti…
Phase 2 • Sponsor: Holy Stone Healthcare Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a simpler scope technique match the complex one for large colon growths?
Disease control OngoingResearchers compare two ways to remove large, non-cancerous growths from the colon. One method, endoscopic mucosal resection, removes the growth in pieces. The other, endoscopic submucosal dissection, removes it in one piece but takes longer and carries more risk. The trial tests…
Sponsor: José Carlos Marín Gabriel • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Targeted drug shows promise for rare ROS1 cancers
Disease control OngoingThis study tests a drug called crizotinib in people whose cancer has a specific genetic change called ROS1 translocation. The drug blocks a protein that may help cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. Only 4 people took part,…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Double-Target immunotherapy added to standard care for aggressive cervical cancer
Disease control By invitation onlyResearchers are testing whether adding cadonilimab, an immunotherapy drug, to chemotherapy before and after standard chemoradiation can help women with high-risk, locally advanced cervical cancer. The trial enrolls 20 women who have not received prior treatment. Participants rece…
Sponsor: Hubei Cancer Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: targeted pill combo in final testing
Disease control OngoingThis phase 3 study tests whether adding alpelisib (a targeted pill) to fulvestrant (a hormone-blocking shot) can slow cancer growth in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. Participants must have already tr…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody takes aim at Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial tests a new antibody drug called Hu8F4 in 72 people with advanced blood cancers like leukemia and myelodysplastic syndrome. The goal is to find the safest dose and see if it can slow or stop cancer growth. Researchers will also track how long patients live …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug combo aims to stall breast cancer in patients with key gene mutation
Disease control OngoingThis phase II study tests whether adding alpelisib (a targeted pill) to standard fulvestrant (a hormone-blocking shot) can delay cancer growth in Chinese men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that has wors…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug duo targets hard-to-treat blood cancers
Disease control OngoingThis study tests a new drug, seclidemstat, combined with a standard drug, azacitidine, for people with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to find the best dose and see if the combination can shrink or control the cancer. About 2…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can adding surgery or radiation to a targeted pill slow lung cancer better?
Disease control OngoingThis study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus lo…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims to deepen remission in early CML
Disease control OngoingThis study tests whether adding ASTX727 to the standard drug dasatinib can better control chronic myeloid leukemia (CML) in newly diagnosed patients. About 70 adults with a specific genetic marker (Philadelphia chromosome) will receive both pills. The goal is to see if the combin…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immune cells take on tough tumors in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…
Phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to tackle melanoma that resists treatment
Disease control OngoingThis phase 2 trial is testing whether a combination of two drugs, enfortumab vedotin and pembrolizumab, can shrink tumors in people with advanced melanoma that has worsened after standard therapy. The study will enroll 60 adults with unresectable stage III or IV melanoma. Researc…
Phase 2 • Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for tough prostate cancer: drug combo trial launches
Disease control OngoingThis Phase II trial tests a new drug, JSB462 (luxdegalutamide), combined with a radioactive therapy (Pluvicto) in 138 men with PSMA-positive metastatic castration-resistant prostate cancer that has progressed after prior treatments. The study aims to see if the combination works …
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Freezing tumors to boost cancer treatment: early trial underway
Disease control OngoingThis early-phase trial tests a freezing treatment called cryotherapy, given before and during standard chemoradiation, for people with locally advanced esophageal cancer. The main goal is to find the safest number of cryotherapy sessions. Researchers will also check if the freezi…
Phase 1 • Sponsor: Hunter Holmes Mcguire Veteran Affairs Medical Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill combo aims to keep advanced breast cancer in check
Disease control OngoingThis Phase 3 study tests whether adding the targeted drug alpelisib to standard maintenance therapy (trastuzumab and pertuzumab) can help people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation) live longer without their cancer growing…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immunotherapy duo takes on resistant germ cell tumors
Disease control OngoingThis phase 2 trial tests two immunotherapy drugs, durvalumab and tremelimumab, in 30 adults with relapsed or refractory germ cell tumors. The goal is to see if the combination can shrink tumors or lower tumor markers. Participants must have measurable disease and have progressed …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cocktail of drugs and radiation aims to boost stomach cancer treatment before surgery
Disease control OngoingThis pilot study tests whether giving a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with chemotherapy and radiation therapy before surgery can help treat stomach cancer that can be surgically removed. The study includes 32 participants and primarily lo…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to slow prostate cancer spread
Disease control OngoingThis study tests a new drug, JSB462, combined with standard therapy (abiraterone) in 150 men whose prostate cancer has spread but still responds to hormone treatment. The goal is to see if the combination lowers PSA levels more effectively and delays cancer growth. Participants w…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Could a shorter radiation zap before surgery be just as good for sarcoma patients?
Disease control OngoingThis study compares the usual 5-week radiation schedule before sarcoma surgery to a shorter 2-week course. Researchers want to see if the shorter course leads to similar wound healing and tumor control. About 168 adults with soft tissue sarcomas in the head, neck, trunk, or limbs…
Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New CAR T-Cell therapy targets Hard-to-Treat multiple myeloma
Disease control OngoingThis early-phase study tests a new treatment for multiple myeloma that has come back or not responded to standard therapy. The treatment uses a patient's own immune cells (T cells) that are modified in the lab to recognize and attack cancer cells carrying a protein called CD138. …
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy shows promise for Radioiodine-Resistant thyroid cancer
Disease control OngoingThis phase 2 trial tests a combination of the immunotherapy drug PDR001 with either trametinib or dabrafenib in 19 patients with thyroid cancer that no longer responds to radioiodine treatment. The goal is to see if the combination can shrink tumors. The study is active but no lo…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cocktail of drugs tested for Tough-to-Treat lymphoma
Disease control OngoingThis phase 2 trial is testing several new drug combinations for people with aggressive B-cell lymphoma that has come back or not responded to standard therapy. About 129 participants will receive one of several experimental combinations, including drugs like ibrutinib and selinex…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New radiation approach may offer shorter, safer treatment for recurrent prostate cancer
Disease control OngoingThis study tests whether a precise, short-course radiation method (SBRT) works as well as a slightly longer radiation approach (hypofractionated radiotherapy) for men whose prostate cancer has come back or spread to a few spots after surgery. About 118 participants will receive o…
Phase 3 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cancer drug combo enters human testing
Disease control OngoingThis early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug iberdomide takes on lenalidomide in battle to keep myeloma at bay
Disease control OngoingThis phase 3 trial tests whether iberdomide is better than lenalidomide as maintenance therapy after a stem cell transplant in people newly diagnosed with multiple myeloma. About 1,200 participants will receive either drug to see which one delays cancer progression longer. The st…
Phase 3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo aims to wipe out lingering leukemia before transplant
Disease control OngoingThis phase 2 trial tests whether a combination of venetoclax and azacitidine can clear measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) who still have or develop leftover cancer cells after initial chemotherapy, and before a stem cell transplant. Abou…
Phase 2 • Sponsor: Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a Platelet-Boosting drug help control a rare bone marrow disorder?
Disease control OngoingResearchers are observing how well eltrombopag works in adults with hypocellular myelodysplastic neoplasms, a bone marrow condition that lowers blood cell counts. The study follows patients in Italy who receive eltrombopag alone or with immunosuppressive therapy as part of routin…
Sponsor: Fondazione Italiana Sindromi Mielodisplastiche-ETS • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill hopes to boost blood in bone marrow disease
Disease control OngoingThis study tests an experimental drug, HT-6184, in adults with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). The goal is to see if the drug can improve blood counts and reduce the need for transfusions. Participants take…
Phase 2 • Sponsor: Halia Therapeutics, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Custom RNA vaccine aims to supercharge cancer immunotherapy
Disease control PausedThis early-phase trial tests a personalized RNA nanoparticle vaccine made from a patient's own tumor. The goal is to help anti-PD-1 immunotherapy work better in people with advanced melanoma or soft tissue sarcoma whose cancer has progressed on standard treatment. Up to 18 partic…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a targeted drug outperform chemotherapy in Tough-to-Treat nasopharyngeal cancer?
Disease control OngoingThis phase III trial compares an experimental drug called YL201 with standard chemotherapy in people whose nasopharyngeal carcinoma has returned or spread and no longer responds to PD-(L)1 inhibitors and at least two prior chemotherapy regimens. About 400 participants will receiv…
Phase 3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New study tests everolimus for kidney tumors in TSC patients
Disease control OngoingThis study looks at how safe and effective the drug everolimus is for Taiwanese adults with tuberous sclerosis complex (TSC) who have kidney tumors called angiomyolipomas. Four participants will take the drug and be monitored for side effects and tumor shrinkage. The goal is to c…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Robot-Assisted colonoscopy: a safer scope?
Disease control OngoingThis study will test a new robotic device called the Triton 1.5 System for performing colonoscopies, which are exams to look for colon cancer. About 40 adults who need a routine colonoscopy will take part. The main goal is to see if the robot is safe and can successfully complete…
Sponsor: Neptune Medical • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Cancer drug RVU120 gets extended trial for ongoing patients
Disease control By invitation onlyThis study offers continued RVU120 treatment to up to 10 patients with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from the drug in an earlier trial. The main goal is to monitor safety and see how long patients c…
Phase 2 • Sponsor: Ryvu Therapeutics SA • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Shorter, stronger radiation beams tested for prostate cancer
Disease control OngoingThis study tests whether a shorter, more intense radiation treatment (5 sessions) is better than the standard 20-session approach for men with intermediate- or high-risk prostate cancer that hasn't spread. The goal is to improve cancer control while keeping side effects low. Abou…
Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New shot shrinks skin cancer before surgery in early trial
Disease control OngoingThis study tests an experimental drug called BO-112, injected directly into basal cell skin cancer tumors before they are surgically removed. The goal is to see if the drug is safe and helps shrink or eliminate the cancer. About 60 adults with low- or high-risk basal cell carcino…
Phase 2 • Sponsor: Highlight Therapeutics • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Lifeline for ALK cancer patients: continued access to ceritinib
Disease control OngoingThis study offers continued treatment with the drug ceritinib to people with ALK-positive cancers who were already benefiting from it in a previous Novartis study. The main goal is to track safety and side effects over time. About 233 participants will receive the drug as long as…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Phase 1/2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy aims to keep multiple myeloma in check longer
Disease control OngoingThis phase 3 study tests whether adding daratumumab to the standard drug lenalidomide as maintenance therapy after a stem cell transplant can better control multiple myeloma. About 1,100 participants will be randomly assigned to receive either lenalidomide alone or lenalidomide p…
Phase 3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New pill takes on rare salivary gland and colon cancers
Disease control OngoingThis early-stage trial is testing an experimental oral drug called RGT-61159 in about 105 people with two types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to c…
Phase 1 • Sponsor: Rgenta Therapeutics Inc • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control OngoingThis early-stage trial tests whether combining two drugs, ceritinib and nivolumab, is safe and effective for people with a specific genetic subtype of advanced lung cancer called ALK-positive NSCLC. About 57 adults with stage IIIB or IV disease will receive the combination. The m…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Virus plus radiation may shrink sarcomas before surgery
Disease control OngoingThis study tests whether a cancer-killing virus (T-VEC) combined with radiation can shrink soft tissue sarcomas before surgery. About 40 adults with newly diagnosed, removable sarcomas will receive the virus injected into the tumor plus radiation. The main goals are to see how ma…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Immunotherapy added to standard treatment aims to stop esophageal cancer from returning
Disease control OngoingResearchers are testing whether adding the immunotherapy drug camrelizumab to chemotherapy or chemoradiotherapy before surgery helps people with locally advanced esophageal squamous cell carcinoma. The trial enrolls adults with resectable tumors who have not received prior treatm…
Phase 3 • Sponsor: Zhigang Li • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Brain cancer trial: one big dose or several small doses of radiation?
Disease control OngoingThis phase III trial tests whether giving several small doses of radiation (fractionated radiosurgery) after removing a brain tumor is better than a single large dose. About 242 patients with cancer that spread to the brain will be randomly assigned to one of the two radiation pl…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo targets CD46 in aggressive prostate cancer
Disease control OngoingResearchers are testing a new drug called FOR46, which seeks out a protein called CD46 on cancer cells, together with enzalutamide, a standard hormone therapy, in men whose prostate cancer has spread and worsened despite prior treatment with abiraterone. The trial aims to find th…
Phase 1/2 • Sponsor: Rahul Aggarwal • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo aims to stall rare Cancer's spread
Disease control OngoingThis study compares the drug palbociclib alone versus palbociclib plus cemiplimab in 77 people with advanced dedifferentiated liposarcoma that cannot be removed by surgery. Palbociclib blocks enzymes that help cancer cells grow, while cemiplimab boosts the immune system to attack…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New vaccine combo shows promise in ovarian cancer fight
Disease control OngoingThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRαDC) with an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells. The trial …
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Promising drug may shrink inoperable tumors in kids with rare genetic condition
Disease control OngoingThis study tests a drug called selumetinib in children and young adults (ages 3-18) with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink or slow the growth of these tumors. Participants take the dru…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Engineered immune cells take aim at CD70-Positive cancers in new trial
Disease control CancelledThis early-phase trial tests a new type of immunotherapy called CD70 CAR T cells in people with lymphoma, myeloma, and certain solid tumors (like kidney cancer and sarcomas) that have come back or not responded to standard treatments. The immune cells are modified in the lab to r…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Liver tumor treatment gets a targeted boost: Drug-Loaded beads take aim at metastases
Disease control OngoingThis early-phase trial is testing a new approach for people with liver metastases (cancer that has spread to the liver from elsewhere). Doctors are using a procedure called TACE to deliver the drug bevacizumab directly into the liver's blood vessels, aiming to concentrate the tre…
Phase 1/2 • Sponsor: Pardis Noor Medical Imaging and Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Chemotherapy delivered directly to abdomen shows promise in early trial
Disease control OngoingThis early-phase trial tests a combination of three drugs for people whose appendix or colon cancer has spread to the lining of the abdomen (peritoneal carcinomatosis). After surgery to remove visible tumors, patients receive chemotherapy directly into the abdomen (oxaliplatin) p…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control OngoingThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a simple ketone drink reduce the need for surgery in FAP patients?
Disease control By invitation onlyThis study tests whether a daily ketone supplement (BHB) is safe and tolerable for people with Familial Adenomatous Polyposis (FAP), a genetic condition that causes many colon polyps and often leads to surgery. Twenty participants will take the supplement for two weeks to see if …
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a Sugar-Blocking pill boost immunotherapy for tough cancers?
Disease control OngoingThis phase 2 trial tests whether adding an experimental pill (GB1211) to the immunotherapy drug pembrolizumab (Keytruda) works better than Keytruda alone for people with advanced melanoma or head and neck cancer. The study will enroll 92 participants and measure how many patients…
Phase 2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill could outperform current KRAS lung cancer drugs
Disease control OngoingThis phase 3 trial compares a new drug, divarasib, to two existing targeted therapies (sotorasib and adagrasib) in 338 people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has progressed after prior treatment. Participants take …
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for stomach cancer: targeted combo therapy enters final trial phase
Disease control OngoingThis study tests a new drug called ASKB589 combined with chemotherapy and an immunotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread. The trial includes 780 participants whose tumors have a specific marker (CLDN18.2). The goal is to see …
Phase 3 • Sponsor: AskGene Pharma, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Radiation boosts liver size, paving way for cancer surgery
Disease control OngoingThis study is for people with liver cancer who need surgery but don't have enough healthy liver left. Doctors use a special radiation treatment (Y90) to help the liver grow larger. Once the liver is big enough, patients can have surgery to remove the cancer. The study compares st…
Sponsor: Northwestern University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat brain cancer
Disease control OngoingThis early-phase study tests a combination of two drugs, acalabrutinib and durvalumab, in people with primary central nervous system (CNS) lymphoma—a rare and aggressive brain cancer. The study includes up to 25 patients whose cancer has returned after prior treatment or who cann…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can an HDAC inhibitor wipe out residual leukemia cells?
Disease control OngoingResearchers are studying whether the drug chidamide can help keep high-risk acute myeloid leukemia (AML) in remission when used as maintenance therapy. The trial enrolls adults with specific genetic features and measurable residual disease who are not receiving a stem cell transp…
Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can myeloma treatment work without steroids?
Disease control OngoingResearchers are testing whether daratumumab and lenalidomide can treat newly diagnosed multiple myeloma without adding steroids. The trial enrolls patients who are not candidates for high-dose chemotherapy and have not received prior treatment. The goal is to see how often infusi…
Phase 2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Experimental drug TAK-243 targets tough blood cancers in early trial
Disease control OngoingThis early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Radiation probe targets Hard-to-Treat tumors
Disease control By invitation onlyResearchers are testing a new molecular probe called 177Lu-NI-FAPI that aims to deliver radiation directly to tumor cells. The probe targets two features common in aggressive tumors: low oxygen levels and fibroblast activation proteins. The study enrolls up to 20 adults with adva…
Phase 1/2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New Four-Drug cocktail aims to tackle tough myeloma
Disease control OngoingThis phase 2 trial tests a combination of four drugs—isatuximab, carfilzomib, pomalidomide, and dexamethasone—in 30 patients with multiple myeloma that has relapsed or become resistant to treatment. The goal is to see how many patients respond to this regimen. All participants ha…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a rheumatoid arthritis drug tame Immunotherapy's side effects?
Disease control OngoingThis study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Universal donor immune cells tested against tough childhood cancer
Disease control OngoingResearchers are testing whether natural killer (NK) cells from a universal donor can be safely given with standard chemotherapy drugs and an immune-targeting antibody to children and young adults with neuroblastoma that has returned or stopped responding. The NK cells are modifie…
Phase 1/2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Lung cancer radiation gets a precision boost: trial aims to hit tumors harder, spare healthy tissue
Disease control OngoingThis study tests whether giving a higher radiation dose directly to the tumor, while keeping the standard dose to surrounding healthy tissue, can improve outcomes for people with stage II to IIIB non-small cell lung cancer. About 146 participants will receive either photon (IMRT)…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New cocktail targets tough lymphoma
Disease control OngoingThis early-phase study tests a combination of three drugs (ibrutinib, lenalidomide, and rituximab) in people with mantle cell lymphoma that has returned or not responded to prior treatment. The main goal is to find the safest dose of this combination by monitoring side effects. U…
Phase 1 • Sponsor: Hackensack Meridian Health • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug duo targets rare kidney cancer in early trial
Disease control OngoingThis study tests a combination of two drugs (fruquintinib and serplulimab) as the first treatment for people with a rare type of kidney cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors or slow the disease. About 39 adults will t…
Phase 2 • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to halt lung cancer growth
Disease control OngoingThis study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase 1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo aims to extend life in tough bladder cancer cases
Disease control OngoingThis study tests whether adding the drug eribulin to standard chemotherapy can help people with advanced bladder cancer live longer. It is for patients whose cancer has spread and no longer responds to immunotherapy. About 184 participants will receive either the new combination …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for tough hodgkin lymphoma: immune drugs tested alone or together
Disease control OngoingThis study tests two immune-boosting drugs, ipilimumab and nivolumab, in people with classic Hodgkin lymphoma that has returned or not responded to prior therapy. The goal is to see if giving these drugs alone or together can shrink tumors. The trial involves 13 adults with measu…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo targets deadly brain cancer in early trial
Disease control OngoingThis early-phase study tests whether adding the drug ibrutinib to standard radiation and chemotherapy is safe for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 36 adults with specific tumor types (MGMT methylated or unmethylated) will receive differ…
Phase 1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Sound waves vs. prostate cancer: new MRI-Guided treatment tested
Disease control PausedThis study tests a procedure called TULSA that uses MRI images to guide high-energy ultrasound waves to destroy prostate cancer tumors. About 21 adults with early-stage prostate cancer that shows up on MRI will receive this heat-based treatment. The goal is to see if the approach…
Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise for rare skin cancer in early trial
Disease control OngoingThis early-phase trial tests a new drug called tulmimetostat (DZR123) in 24 people with advanced mycosis fungoides or Sézary syndrome, rare types of skin lymphoma. Participants must have tried at least one prior treatment. The study aims to see if the drug is safe and tolerable, …
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for older leukemia patients with gentler drug combo
Disease control OngoingThis study tests a new two-drug combination (ASTX727 and venetoclax) in adults with acute myeloid leukemia who are 75 or older, or have health issues that make standard strong chemotherapy too risky. The goal is to see if the drugs work well together and can control the leukemia.…
Phase 1/2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can adding linperlisib to standard chemotherapy improve outcomes in rare T-Cell lymphoma?
Disease control OngoingResearchers are testing whether adding the experimental drug linperlisib to standard CHOP chemotherapy helps people with newly diagnosed peripheral T-cell lymphoma. The trial enrolls about 44 participants who have not received prior treatment. Everyone receives six cycles of the …
Phase 1/2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for hard-to-treat lung cancer: experimental drug targets MET gene
Disease control OngoingThis study tests an experimental drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 participants will take part.
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Drug could slash surgeries for rare airway disease
Disease control OngoingThis phase II trial tests whether bevacizumab, a drug that blocks blood vessel growth, can lengthen the time between surgeries for adults with recurrent respiratory papillomatosis (RRP), a rare condition causing wart-like growths in the airways. Participants receive 11 doses of t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Could a Telomere-Targeting drug revive immunotherapy in lung cancer?
Disease control OngoingThis phase 2 trial tests a new drug called THIO, which targets telomeres in cancer cells, followed by the immunotherapy cemiplimab (LIBTAYO) in people with advanced non-small cell lung cancer. The study includes about 227 participants whose cancer has progressed after initial tre…
Phase 2 • Sponsor: Maia Biotechnology • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New study tests aggressive BP management to protect heart and kidneys in cancer patients
Disease control OngoingThis phase II trial tests whether intensive blood pressure management (targeting systolic BP below 120 mmHg) is better than standard care (below 140 mmHg) for patients with advanced kidney or thyroid cancer starting anti-angiogenic TKI therapy. The study enrolls 61 participants a…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can an oral HER2 drug boost Chemo's punch in HER2-Low breast cancer?
Disease control OngoingResearchers are testing whether adding pyrotinib, an oral drug that targets HER2-family proteins, to standard chemotherapy helps shrink HER2-low, hormone receptor-positive breast cancer before surgery. The trial enrolls about 48 women with early or locally advanced disease. Every…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug cocktail shows promise for leukemia patients
Disease control OngoingThis study tests a combination of four drugs (ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab) as the first treatment for people with chronic lymphocytic leukemia (CLL) who have a specific genetic marker (mutated IGHV gene). The goal is to see if this combo can achieve…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise against tough breast cancer
Disease control OngoingThis Phase 2 trial tests an experimental drug called CFI-400945 in 51 people with advanced or metastatic breast cancer that has already been treated with chemotherapy. The goal is to see if the drug can shrink tumors or slow the disease. Participants take the drug in 28-day cycle…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Virus therapy joins Chemo-Radiation in fight against rectal cancer
Disease control OngoingThis early-phase trial tests a new treatment called NG-350A, a virus designed to stimulate the immune system inside tumors, combined with standard chemoradiotherapy for people with locally advanced rectal cancer. The study aims to see if this combination can improve the chance of…
Phase 1 • Sponsor: Akamis Bio • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can breast radiation be cut from three weeks to one?
Disease control CancelledResearchers compare two schedules of partial breast irradiation after breast-conserving surgery in women with low-risk early breast cancer. One group receives radiation daily for one week, the other for three weeks. The trial measures breast appearance three years later and track…
Sponsor: Fudan University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Triple-Drug cocktail targets Hard-to-Treat mesothelioma
Disease control OngoingThis phase 2 trial tests a combination of three types of drugs—an immunotherapy (pembrolizumab), a targeted therapy (lenvatinib), and chemotherapy (pemetrexed plus cisplatin or carboplatin)—as a first treatment for people with advanced malignant pleural mesothelioma that cannot b…
Phase 2 • Sponsor: Hyogo Medical University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
PET scans guide Nivolumab-Chemo combo in relapsed hodgkin lymphoma
Disease control OngoingResearchers test a treatment plan for adults with Hodgkin lymphoma that has come back or stopped responding to initial therapy. Participants receive nivolumab, an immunotherapy, plus three chemotherapy drugs. PET scans help doctors decide how much treatment each person needs. The…
Phase 1/2 • Sponsor: St. Petersburg State Pavlov Medical University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New Antibody-Like drug joins forces with standard chemo to fight lung cancer
Disease control OngoingThis early-phase trial tests a new drug called BI 764532 (obrixtamig) added to standard chemotherapy and immunotherapy for people with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. About 46…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Triple drug combo aims to slow HR+/HER2- advanced breast cancer
Disease control OngoingResearchers are testing whether adding apatinib, a drug that blocks blood vessel growth, to a CDK4/6 inhibitor and hormone therapy helps control HR+/HER2- advanced breast cancer. The trial enrolls women aged 18 to 75 with confirmed HR-positive, HER2-negative invasive breast cance…
Phase 2 • Sponsor: Fudan University • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Cancer drug cabozantinib takes on rare, Fast-Growing tumors
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in 35 people with high-grade neuroendocrine tumors that have worsened after at least one prior treatment. These are rare, fast-growing cancers with limited options. The study aims to see if cabozantinib can shrink tumors or slow thei…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Hard-to-Treat leukemia: targeted pill combined with chemotherapy enters human trials
Disease control OngoingThis early-stage trial is testing a new oral drug called SNDX-5613 alongside standard intensive chemotherapy in people newly diagnosed with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A, NPM1, or NUP98). The study aims to see if the combination is safe and…
Phase 1 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo shows promise for chinese men with advanced prostate cancer
Disease control OngoingThis phase 3 study tested whether adding enzalutamide (Xtandi) to standard hormone therapy (ADT) helps Chinese men with metastatic hormone-sensitive prostate cancer. 180 participants received either enzalutamide plus ADT or a placebo plus ADT. The main goal was to see how long it…
Phase 3 • Sponsor: Astellas (Beijing) Pharmaceutical R&D Co., Ltd. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can tumor genes decide who keeps their bladder?
Disease control OngoingResearchers at Dana-Farber Cancer Institute are testing whether information from a bladder tumor's genes, combined with how the tumor responds to chemotherapy, can help doctors and patients decide between bladder-sparing chemoradiation and surgery to remove the bladder. The study…
Early phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Smart scans guide tailored therapy for hodgkin lymphoma patients
Disease control OngoingThis study tests a personalized approach for people with early-stage Hodgkin lymphoma. Doctors use PET scans to decide if standard chemotherapy alone is enough or if adding immunotherapy drugs can improve results. The goal is to boost survival while limiting unnecessary treatment…
Phase 2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Four-Drug combo aims to push High-Risk myeloma into deep remission
Disease control OngoingResearchers are testing whether adding selinexor to carfilzomib, daratumumab, and dexamethasone helps patients with high-risk multiple myeloma that has returned or stopped responding to treatment. Participants must have received one to three prior lines of therapy and be sensitiv…
Phase 2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo targets rare, aggressive cancer in early trial
Disease control OngoingThis early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat prostate cancer
Disease control OngoingThis study tests a combination of two drugs—cabazitaxel (a chemotherapy) and enzalutamide (a hormone blocker)—in people with prostate cancer that has spread and stopped responding to standard hormone therapy. The goal is to find the safest dose and see if the combination can lowe…
Phase 1/2 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cocktail aims to keep myeloma at bay longer
Disease control OngoingThis phase 2 trial is testing whether adding the drug daratumumab to a standard treatment plan helps people with newly diagnosed multiple myeloma live longer without their cancer getting worse. The study involves 50 participants and uses a combination of daratumumab, carfilzomib,…
Phase 2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental cell therapy aims to boost immune attack on breast cancer
Disease control PausedThis early-phase study tests the safety of giving specially grown immune cells (T cells) to people with metastatic HER2-positive breast cancer. Participants first receive a vaccine made from their own immune cells plus two drugs (pepinemab and trastuzumab) to help the body fight …
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Immunotherapy boost may wipe out stubborn leukemia cells
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard tyrosine kinase inhibitors (TKIs) can eliminate tiny amounts of leftover leukemia cells in people with chronic myeloid leukemia (CML). About 40 adults with CML who still have detectable cancer marker…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can some breast cancer patients safely skip extra radiation?
Disease control CancelledThis trial tests whether women with advanced breast cancer (cN3) who had chemotherapy before surgery can safely skip an extra radiation dose to lymph nodes that no longer show signs of cancer. Half of the participants receive the standard extra radiation boost, while the other ha…
Sponsor: Fudan University • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Walk or cycle before cancer treatment: new study tests exercise boost
Disease control OngoingThis early-phase study tests whether 30 minutes of moderate exercise (like walking or cycling) right before standard immunotherapy can improve treatment for certain skin cancers (melanoma, squamous cell carcinoma, Merkel cell carcinoma). About 22 adults will exercise before each …
Early phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could taking a break from melanoma drugs be just as good?
Disease control OngoingThis phase 2 trial compares two ways of taking the targeted drugs dabrafenib and trametinib for advanced BRAF-mutant melanoma: continuously versus with planned breaks. About 280 people with stage III or IV melanoma that cannot be surgically removed are participating. The goal is …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug BNT314 enters first human safety trial
Disease control OngoingThis study is the first time BNT314 is being tested in humans. It aims to see if the drug is safe for people with advanced solid tumors that have not responded to other treatments. About 41 participants will receive different doses to find the highest dose that is still safe and …
Phase 1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug cocktail shows promise in early cancer trial
Disease control OngoingThis phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a Two-Drug chemo combo shrink BRCA breast tumors before surgery?
Disease control OngoingResearchers test whether giving mitomycin plus carboplatin before surgery helps people with BRCA1 or BRCA2 mutations and locally advanced triple-negative breast cancer. The trial compares this combination, followed by paclitaxel, against standard chemotherapy. About 30 adults wit…
Sponsor: N.N. Petrov National Medical Research Center of Oncology • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New Light-Based combo tackles tough lung cancers
Disease control CancelledThis phase II trial tests a new approach for advanced non-small cell lung cancer that hasn't responded to standard treatments. It combines photoimmunotherapy (ASP-1929), a light-activated drug that targets cancer cells, with cemiplimab, an immunotherapy that boosts the immune sys…
Phase 2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for rare inflammatory disease: pacritinib trial begins
Disease control OngoingThis study tests a drug called pacritinib for people with VEXAS syndrome, a rare genetic disease that causes severe inflammation. About 78 adults will receive either the drug or a placebo to see if it controls symptoms and reduces flare-ups. The goal is to find a safe and effecti…
Phase 2 • Sponsor: Swedish Orphan Biovitrum • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Targeted drug ibrutinib shows promise against rare leukemia
Disease control OngoingThis phase 2 trial tests the drug ibrutinib in 44 people with hairy cell leukemia that has come back after treatment. Ibrutinib works by blocking a protein that helps cancer cells grow. The main goal is to see how many patients achieve remission within 32 weeks.
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug duo aims to control rare lymphoma without chemotherapy
Disease control OngoingThis study tests whether combining zanubrutinib (a targeted pill) with rituximab (an antibody infusion) can shrink or control MALT lymphoma, a slow-growing cancer of the lymph nodes and organs. About 42 adults with newly diagnosed advanced disease or lymphoma that returned after …
Phase 2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New Two-Drug combo targets Hard-to-Treat myeloma in early trial
Disease control OngoingThis early-stage study is testing whether a combination of two drugs—elranatamab (given as a shot) and iberdomide (taken as a pill)—is safe and tolerable for people with multiple myeloma that has returned or stopped responding to prior treatments. The trial will enroll about 87 p…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Supercharged immune cells injected into brain to fight tumors
Disease control OngoingThis early-phase trial tests a new approach for people with HER2-positive brain tumors that have come back or not responded to standard treatment. Researchers take the patient's own T cells, attach a special antibody (anti-HER2) to them, and inject these 'CAR T cells' directly in…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat liver cancer
Disease control PausedThis early-phase trial tests a new treatment called RPCAR01 for people with advanced liver cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein call…
Phase 1 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New study aims to spare healthy breast tissue during cancer surgery
Disease control OngoingThis study compares two surgical approaches for breast cancer: one that removes extra tissue around the tumor (routine cavity shave margins) and one that uses a special device (Savi Scout®) to guide removal of only suspicious margins. About 204 women with early-stage breast cance…
Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a shorter radiation course beat anal cancer?
Disease control By invitation onlyThis phase 2 trial is testing whether a shorter course of radiation therapy, given alongside standard chemotherapy, can effectively treat high-risk anal cancer. The standard treatment typically requires about 6 weeks of daily radiation, which can be a heavy burden for patients. T…
Phase 2 • Sponsor: University of Vermont Medical Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Blood test could guide stronger chemo for colon cancer
Disease control OngoingResearchers are testing whether a blood test that detects tiny amounts of tumor DNA can guide chemotherapy after surgery for early colon cancer. The trial compares two chemotherapy regimens: an intensive one called FOLFOXIRI and a standard one called CAPOX. They want to see if th…
Phase 2 • Sponsor: Fundación para la Investigación del Hospital Clínico de Valencia • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo takes on tough lung cancer
Disease control OngoingThis early-stage trial tests a new antibody-like drug called BI 764532 alongside standard chemotherapy in adults with advanced small cell lung cancer that has returned after platinum-based treatment. The main goal is to find a safe dose and check for side effects. About 69 partic…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a cancer vaccine plus hormone drugs slow prostate cancer?
Disease control OngoingThis study tests whether adding the immune-boosting drug Sipuleucel-T (Provenge) to standard hormone therapy can help men with advanced prostate cancer that is no longer responding to hormones alone. The trial involves 26 participants who will receive either Sipuleucel-T alone or…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill shows promise for rare tumor in japanese patients
Disease control OngoingThis phase 2 study tests the drug nirogacestat in 20 Japanese adults with desmoid tumors that are growing. The goal is to see if the drug can shrink tumors or stop them from getting worse. Participants take nirogacestat as an oral tablet, and researchers will monitor tumor respon…
Phase 2 • Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Adult leukemia patients get Kid-Style chemo combo in new trial
Disease control OngoingThis phase 2 trial is testing whether a combination of chemotherapy drugs typically used in children can be safe and effective for adults aged 18 to 60 with newly diagnosed Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). The study aims to see if this 'pediatr…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New proton therapy aims to shield memory in kids with brain cancer
Disease control OngoingThis study tests a new way to give proton radiation to children with low-grade glioma, a common brain tumor. The goal is to avoid the hippocampus, a brain area key for memory, to reduce long-term memory loss. About 74 children will receive this targeted radiation, and researchers…
Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
PET scans may let melanoma patients stop treatment sooner
Disease control OngoingThis study looks at whether doctors can safely stop standard anti-PD-1 immunotherapy early in people with advanced melanoma that cannot be surgically removed. By using PET/CT scans and tumor biopsies as guides, the goal is to reduce treatment side effects and burden without harmi…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug cocktail targets rare eye cancer
Disease control OngoingThis phase II trial tests two drugs—olaparib and pembrolizumab—together in 12 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can shrink tumors or slow the disease. The study is active but no longer recruiting, and res…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Targeted pill takes aim at rare cancer mutations
Disease control OngoingThis phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for NF1 patients: drug shows promise against inoperable tumors
Disease control OngoingThis study tests a drug called selumetinib in adults with neurofibromatosis type 1 (NF1) who have nerve tumors that cannot be removed by surgery. The goal is to see if the drug can shrink these tumors or slow their growth. Participants take the drug twice daily and are monitored …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for lung cancer: YL201 takes on relapsed SCLC in major trial
Disease control OngoingThis Phase 3 study compares a new drug called YL201 to the standard treatment topotecan in 438 adults with relapsed small cell lung cancer. The goal is to see if YL201 helps people live longer. Participants receive either YL201 by infusion every three weeks or topotecan by inject…
Phase 3 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New study tests which drug gives myeloma patients better daily life
Disease control OngoingThis phase 2 trial compares daratumumab and lenalidomide as maintenance therapy for people with newly diagnosed multiple myeloma who have responded well to initial treatment. The main goal is to see which drug provides better health-related quality of life, measured through quest…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental vaccine takes on deadly childhood brain tumors
Disease control OngoingThis phase 1 trial tests a peptide vaccine designed to target a specific mutation (H3K27M) found in certain aggressive brain tumors called diffuse midline gliomas. Fifteen newly diagnosed patients receive the vaccine along with the immunotherapy drug atezolizumab after standard r…
Phase 1 • Sponsor: German Cancer Research Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo aims to fight resistant lung cancer
Disease control OngoingThis phase 3 trial tests whether adding savolitinib to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutant, MET-positive non-small cell lung cancer). About 412 participants will receive either the combination or a placebo plus osim…
Phase 3 • Sponsor: Hutchmed • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug targets Sugar-Coated proteins on cancer cells
Disease control OngoingResearchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…
Phase 1 • Sponsor: Phost'In Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a daily aspirin boost ovarian cancer treatment?
Disease control PausedThis early-phase study is testing whether taking a daily 325 mg aspirin alongside standard chemotherapy can reduce immune-suppressing cells in ovarian, fallopian tube, or peritoneal tumors. About 100 women will take either aspirin or a placebo for up to 5 cycles of chemo. The goa…
Early phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a combination of two oral drugs, olaparib and ASTX727, in adults with advanced solid tumors that have mutations in genes like BRCA1, BRCA2, PALB2, ATM, or CHEK2. The main goals are to find the safest dose and to check for side effects. About 18 partic…
Phase 1 • Sponsor: Varun Monga, MBBS • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental vaccine targets breast cancer cells in the brain
Disease control OngoingThis early-phase trial tests a dendritic cell vaccine given directly into the spinal fluid for people with breast cancer that has spread to the lining of the brain (leptomeningeal disease). The vaccine is designed to train the immune system to attack cancer cells. The main goal i…
Phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Two-Drug combo aims to outsmart recurrent brain tumors
Disease control OngoingThis trial compares a combination of two drugs (cediranib and olaparib) against a single drug (bevacizumab) in people whose glioblastoma has returned after prior treatment. The goal is to see if the combination can delay tumor growth better than the standard approach. Participant…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Immunotherapy combo aims to boost hodgkin lymphoma response in slow responders
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can help children and young adults (ages 3-25) with newly diagnosed classical Hodgkin lymphoma who did not respond well to initial chemo. About 340 participants will receive pemb…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug cocktail could rival standard bladder cancer therapy in major trial
Disease control OngoingThis study tests whether a combination of two chemotherapy drugs (gemcitabine and docetaxel, or GEMDOCE) works as well as the standard BCG treatment for people with a high-grade, non-muscle invasive bladder cancer that hasn't been treated before. About 870 adults will be randomly…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat bile duct cancer
Disease control OngoingThis study tests a combination of two drugs, candonilimab and LM-302, in people with advanced biliary tract cancer that has stopped responding to standard chemotherapy and immunotherapy. The goal is to see if the combination can shrink tumors or control the disease. About 78 part…
Phase 1/2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for advanced breast cancer: drug combo trial opens
Disease control OngoingThis early-phase study tests a new drug called OP-1250 (palazestrant) combined with other targeted therapies in people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find safe doses and check for side effects. About 190 adults will joi…
Phase 1 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Engineered donor cells aim to beat blood cancer without severe side effects
Disease control OngoingThis study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug cocktail aims to tackle Hard-to-Treat cancers
Disease control OngoingThis early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New radiation boost may improve rectal cancer treatment
Disease control OngoingThis study tests whether giving a higher, targeted radiation dose to the main tumor and nearby lymph nodes can improve outcomes for people with locally advanced rectal cancer. About 128 adults whose cancer has not spread beyond the pelvis will receive either standard radiation or…
Phase 3 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a cancer vaccine injections clear warts that Won't go away?
Disease control OngoingThis phase 2 trial tests whether Gardasil-9, a vaccine normally used to prevent HPV infection, can treat warts that have not responded to standard treatments. Researchers inject the vaccine directly into the wart, rather than into a muscle, and compare its effect against a placeb…
Phase 2 • Sponsor: Rush University Medical Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cocktail of cancer drugs shows promise in early trial
Disease control OngoingThis study tests whether combining three different antibodies—BI 770371, pembrolizumab, and cetuximab—can shrink tumors in people with head and neck cancer that has spread or come back. About 91 adults are randomly assigned to one of three treatment groups. The goal is to see if …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a ZAP of radiation before standard care beat back metastatic kidney cancer?
Disease control OngoingThis Phase III trial tests whether giving a highly targeted form of radiation (SAbR) before standard therapy (immunotherapy or targeted pills) helps people with kidney cancer that has spread to 2-5 spots in the body live longer. About 472 participants are randomly assigned to rec…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can spreading out radiation beat a single dose for brain tumors?
Disease control OngoingThis Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New antibody aims to preserve immune checkpoint while fighting cancer
Disease control OngoingResearchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…
Phase 1/2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immunotherapy combo shows promise against rare sarcomas before surgery
Disease control OngoingThis study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) and radiation before surgery can help shrink tumors in people with two rare types of sarcoma. About 32 adults with these cancers that can be surgically removed will receive the treatment an…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo therapy takes on tough lung cancer
Disease control OngoingThis Phase 2 trial is testing an experimental drug called BNT327 combined with standard chemotherapy in 110 people with small-cell lung cancer. One group has untreated extensive-stage disease, while others have cancer that returned after prior treatment. The study aims to see if …
Phase 2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immunotherapy-Chemo cocktail targets Hard-to-Treat MDS
Disease control OngoingThis phase 2 trial tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus a chemotherapy drug (azacitidine) in 99 people with myelodysplastic syndromes (MDS), a type of blood cancer. The goal is to see if the combination improves response rates, especially…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Radioactive seeds take aim at prostate cancer without extra hormones
Disease control OngoingThis study tests whether a one-time procedure called brachytherapy, where tiny radioactive seeds are placed directly into the prostate, can control intermediate risk prostate cancer without needing additional treatments. Three hundred men with specific tumor features (Gleason sco…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for kidney cancer: which drug combo works best after immunotherapy fails?
Disease control OngoingThis study tests two different drug treatments in people with advanced kidney cancer that has spread and continued to grow despite prior immunotherapy. About 90 participants will receive either a combination of lenvatinib and everolimus or cabozantinib alone. The goal is to see w…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New radiation approach aims to cut treatment time and side effects for breast cancer
Disease control PausedThis study tests a shorter, more focused radiation treatment (hypofractionated partial breast irradiation) for women with early-stage breast cancer. The goal is to see if targeting only the tumor site can reduce side effects and improve cosmetic outcomes compared to standard whol…
Phase 2/3 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Freezing therapy offers new hope for tough Barrett's cases
Disease control OngoingThis study tests a freezing device (CryoBalloon) to treat Barrett's esophagus that hasn't improved after multiple standard heat treatments. About 70 adults with precancerous changes in the esophagus will receive the freezing therapy. The goal is to safely remove all abnormal tiss…
Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
No clamps, no stitches: new robotic surgery aims to save more kidney function
Disease control PausedThis study tests a new robotic surgery technique for kidney cancer that avoids clamping blood vessels and using stitches to close the kidney. The goal is to preserve as much kidney function as possible and reduce the risk of long-term kidney disease. About 59 adults with small ki…
Sponsor: University of Florida • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise in controlling Early-Stage leukemia
Disease control OngoingThis study tests a combination of two drugs, dasatinib and venetoclax, in people with early chronic phase chronic myeloid leukemia (CML). The goal is to see if the combination can better control the disease by blocking enzymes that help cancer cells grow. About 155 participants w…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Radiation plus immunotherapy: a new hope for advanced head and neck cancer?
Disease control OngoingThis phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Triple therapy tackles tough lung cancer
Disease control PausedThis early-stage trial tests the safety of combining precise radiation (SBRT) with immunotherapy (durvalumab) and two chemotherapy drugs (platinum and etoposide) for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemo. The study aims t…
Phase 1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Triple-Target CAR T-Cells take on tough lymphomas
Disease control By invitation onlyThis early-phase trial is testing a new type of immunotherapy called tri-specific CAR T-cells that target three proteins (CD19, CD20, CD22) on cancer cells. It is for adults with B-cell lymphomas that have come back or not responded to standard treatments. The study will enroll 1…
Phase 1 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart Treatment-Resistant breast cancer?
Disease control OngoingResearchers are testing two experimental oral drugs, PF-07220060 and PF-07104091, combined with standard hormone therapy in people with advanced breast cancer and other solid tumors. The trial has two parts: one that finds the safest dose and another that tests the combination in…
Phase 1/2 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immunotherapy combo shows promise for bladder cancer patients unable to get chemo
Disease control OngoingThis early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how t…
Early phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Higher dose of breast cancer drug shows promise in Late-Stage trial
Disease control OngoingThis study tested whether a higher dose (500 mg) of the drug fulvestrant works better than the standard dose (250 mg) in postmenopausal women with a certain type of advanced breast cancer that had worsened after previous hormone therapy. The trial involved 736 participants and me…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for tough pancreatic cancer: drug duo tested
Disease control OngoingThis study tests a combination of two drugs, BXCL701 and pembrolizumab, in 22 people with advanced pancreatic cancer that has spread. The goal is to see if this treatment can stop the cancer from growing for at least 18 weeks. Participants must have already tried one prior treatm…
Phase 2 • Sponsor: Georgetown University • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Nasal spray shows promise against deadly brain cancer
Disease control OngoingThis study tests a nasal spray drug called NEO100 (perillyl alcohol) in people with aggressive brain tumors (grade III or IV gliomas) that have come back or worsened. The trial has two phases: first to find the safest dose, then to see if it helps patients live longer. About 49 p…
Phase 1/2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Shorter combo therapy shows promise for advanced melanoma
Disease control OngoingThis phase II trial tested a combination of three drugs—pembrolizumab (Keytruda), dabrafenib (Tafinlar), and trametinib (Mekinist)—in 16 people with advanced melanoma that could not be removed by surgery. The goal was to see if a shorter course of targeted therapy, followed by im…
Phase 2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could adding radiation to immunotherapy keep lung cancer at bay?
Disease control PausedThis study tests whether adding radiation therapy to the usual maintenance drug atezolizumab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 138 participants who have already responded to initial chemo-immunotherapy will be…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise in battling recurrent ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Tiny trial tests Radiation-Immunotherapy cocktail for tough bile duct cancer
Disease control OngoingThis early-phase trial tested a combination of focused radiation and an immunotherapy drug called bintrafusp alfa in just 2 patients with advanced bile duct cancer that had spread. The goal was to find the safest dose and see if the combo could help control the cancer. The study …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental drug combo targets brain cancer metabolism
Disease control OngoingThis early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treat…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New pill could outshine standard shot for tough breast cancer
Disease control OngoingThis Phase 3 study compares a new daily pill, giredestrant, against the standard shot fulvestrant, both given alongside a CDK4/6 inhibitor, in about 1,050 people with ER+/HER2- advanced breast cancer that has become resistant to prior hormone therapy. The goal is to see if girede…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug shows promise for rare blood cancer
Disease control OngoingThis phase 2 study tests acalabrutinib, a targeted drug, in 107 people with Waldenström macroglobulinemia, a rare blood cancer. The goal is to see how well the drug shrinks tumors and controls the disease. Participants either had prior treatment or are new to therapy and cannot t…
Phase 2 • Sponsor: Acerta Pharma BV • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immune cocktail shows promise for Tough-to-Treat melanoma
Disease control OngoingThis phase II trial tests whether adding a growth factor (GM-CSF) to the immunotherapy drug ipilimumab helps people with advanced melanoma live longer. About 245 patients with stage III or IV melanoma that cannot be surgically removed are randomly assigned to get ipilimumab alone…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a Pre-Transplant HPV shot shield patients from cancer?
Disease control OngoingThis phase 2 trial tests whether giving the HPV vaccine (Gardasil 9) to adults before a kidney transplant helps their immune system fight HPV after transplant, when they must take drugs that weaken immunity. About 51 participants will receive the vaccine before surgery, and resea…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo therapy shows promise for rare cancer
Disease control OngoingThis study tests whether combining two drugs, palbociclib and INCMGA00012, is safe and effective for people with advanced liposarcoma, a rare cancer of fat cells. About 42 participants with tumors that cannot be removed by surgery or have spread will receive the combination. The …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could chemo before surgery boost gallbladder cancer survival?
Disease control OngoingThis study looks at whether giving chemotherapy both before and after surgery helps people with stage II-III gallbladder cancer live longer compared to the usual approach of only giving chemo after surgery. About 186 participants will be randomly assigned to one of two groups. Th…
Phase 2/3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Precision radiation may spare brain function in lung cancer patients
Disease control OngoingThis study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail aims to stop leukemia relapse after transplant
Disease control OngoingThis phase 2 trial tests whether combining venetoclax and azacitidine after a stem cell transplant can prevent leukemia from returning in high-risk patients. About 100 adults aged 18-75 with certain types of acute leukemia who are in remission after transplant will receive the dr…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New trial tests smarter radiation to protect memory in lung cancer patients
Disease control OngoingThis phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Robot-Assisted surgery for lung cancer and thymus disease put to the test
Disease control OngoingThis study is testing a new robotic surgery system, the da Vinci SP, for removing part or all of a lung (lobectomy) or the thymus gland (thymectomy) in people with lung cancer, benign lung disease, thymoma, or myasthenia gravis. The goal is to see if the robot can perform these s…
Sponsor: Intuitive Surgical • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for mantle cell lymphoma: transplant combo vs drug alone in major trial
Disease control OngoingThis study tests whether a stem cell transplant followed by the drug rituximab works better than rituximab alone for people with mantle cell lymphoma whose cancer is in first complete remission. About 689 adults aged 18 to 70 are taking part. The goal is to see which approach hel…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Could less be more? new trial tests gentler treatment for anal cancer
Disease control OngoingThis phase II trial is testing whether a lower dose of chemotherapy plus radiation can work as well as the standard dose for early-stage anal cancer. The study includes 252 adults with T1-2N0M0 anal cancer. The goal is to see if the gentler approach controls the disease while imp…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Promising combo targets genetic weakness in advanced prostate cancer
Disease control OngoingThis phase 3 trial is testing whether adding the drug niraparib to standard therapy (abiraterone and prednisone) can slow cancer growth in men with metastatic castration-sensitive prostate cancer who have specific inherited or tumor gene mutations. About 700 participants are bein…
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise for rare ovarian cancer
Disease control OngoingThis pilot phase II study tests whether the drugs fulvestrant and abemaciclib can help control low-grade serous ovarian cancer in women with advanced disease. Up to 18 participants will receive the drugs before and after surgery. The goal is to see how many patients achieve a par…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for tough prostate cancer: drug cocktails under trial
Disease control OngoingThis study tests different combinations of approved drugs in 196 men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The goal is to see which combinations work best to extend life and control the cancer. Participants receive standard hormo…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug acalabrutinib takes on standard combo in untreated CLL
Disease control OngoingThis Phase 3 trial compares the drug acalabrutinib to a combination of chlorambucil and rituximab in people with previously untreated chronic lymphocytic leukemia (CLL). The study includes 155 participants and measures how long the cancer stays under control (progression-free sur…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Real-World check: is talzenna safe for advanced breast cancer?
Disease control CancelledThis study will track 600 people in Korea with advanced breast cancer who are already being prescribed Talzenna. Researchers will watch for side effects and see how well the drug works in everyday medical practice, not in a strict research setting. The goal is to confirm the drug…
Sponsor: Pfizer • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New immunotherapy combo shows promise for advanced liver cancer
Disease control OngoingThis study tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. About 111 participants will receive the drugs to see how safe they are and whether they shrink tum…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Immunotherapy before surgery shows promise for certain colorectal cancers
Disease control OngoingThis trial is testing whether giving the immunotherapy drug pembrolizumab before surgery can improve outcomes for people with high-risk stage 2 or stage 3 colorectal cancer that has a specific genetic feature called mismatch repair deficiency. About 88 participants will receive p…
Phase 2 • Sponsor: University College, London • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for kids with liver cancer: international trial tests smarter chemo combos
Disease control OngoingThis study tests different combinations of chemotherapy drugs, along with surgery, for children and young adults with two types of liver cancer: hepatoblastoma and hepatocellular carcinoma. The goal is to see which combinations work best to stop tumor growth and improve survival.…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Prostate cancer combo: does adding chemo after surgery keep cancer away?
Disease control OngoingThis study looked at 612 men with prostate cancer that had been removed by surgery. It compared standard treatment (hormone therapy plus radiation) against the same treatment plus the chemotherapy drug docetaxel. The goal was to see if adding chemo helps keep the cancer from comi…
Phase 2/3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo shot could tame follicular lymphoma
Disease control OngoingThis study tests two drugs, mosunetuzumab and lenalidomide, together in people with follicular lymphoma, a type of blood cancer. It includes 237 participants and compares giving one drug as a shot under the skin versus through an IV. The goal is to see if the combination is safe …
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo before liver surgery shows promise in early trial
Disease control OngoingThis phase II trial is testing whether giving two drugs—atezolizumab (an immunotherapy) and bevacizumab (which blocks blood vessel growth)—before surgery can help prevent liver cancer from returning. The study enrolled 16 adults with resectable liver cancer. The main goals are to…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a diabetes drug also protect the hearts and prostate of men on hormone therapy?
Disease control OngoingMen with prostate cancer often receive androgen deprivation therapy, which can raise the risk of heart problems and metabolic issues. This trial tests whether adding semaglutide, a GLP-1 receptor agonist, can control cardiovascular risk factors like weight, blood pressure, and ch…
Phase 4 • Sponsor: Hamilton Health Sciences Corporation • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Outpatient immunotherapy tested for hard-to-treat lymphomas
Disease control OngoingResearchers are testing an experimental drug called epcoritamab in adults with diffuse large B-cell lymphoma or classic follicular lymphoma that has come back or stopped responding to earlier treatments. The trial gives the drug as an injection under the skin in increasing doses,…
Phase 2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Five days of radiation instead of weeks: a new test for head and neck cancer
Disease control CancelledResearchers are testing a shorter radiation schedule for people with head and neck cancer who have had surgery. Standard radiation after surgery often takes several weeks, but this trial gives five treatments over five days. The study enrolls 50 adults with high-risk features, su…
Sponsor: All India Institute of Medical Sciences • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can early PET scans guide a gentler, more effective attack on hodgkin lymphoma?
Disease control OngoingThis phase 2 trial tests whether adjusting treatment based on a very early PET scan can improve outcomes and reduce side effects for people with advanced Hodgkin lymphoma. Participants receive brentuximab vedotin plus chemotherapy, with the regimen modified according to how well …
Phase 2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an antibody drug boost standard chemotherapy against an aggressive blood cancer?
Disease control OngoingDiffuse large B-cell lymphoma is an aggressive cancer of immune cells called B cells. This phase 3 trial tests whether adding an experimental antibody drug called epcoritamab to the standard R-CHOP chemotherapy combination improves disease control compared with R-CHOP alone. Abou…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an antibody drug boost transplant results in relapsed myeloma?
Disease control OngoingResearchers are testing whether adding the antibody drug isatuximab to dexamethasone before and after an autologous stem cell transplant helps patients with relapsed multiple myeloma. About 50 adults who already had a transplant and later relapsed will receive three cycles of isa…
Phase 2 • Sponsor: EMN Trial Office S.r.l. Impresa Sociale • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug joins standard chemotherapy in fight against B-Cell lymphoma
Disease control OngoingResearchers are testing whether adding an experimental drug called rocbrutinib to standard R-CHOP chemotherapy is safe and shows early signs of helping adults newly diagnosed with certain B-cell non-Hodgkin lymphomas. The trial enrolls about 112 participants who have not yet rece…
Phase 1 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New antibody tested against aggressive blood cancer
Disease control OngoingResearchers are testing an experimental drug called epcoritamab in Chinese adults with B-cell non-Hodgkin lymphoma. The trial gives epcoritamab alone or combines it with standard chemotherapy drugs (R-CHOP or R2). The main goals are to check safety and see how well the cancer res…
Phase 1/2 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Immunotherapy injection tested against Hard-to-Treat childhood lymphoma
Disease control OngoingStandard treatment cures most children with aggressive mature B-cell lymphomas, but those whose cancer returns or resists therapy have few options. This phase 1b trial tests epcoritamab, an experimental immunotherapy given as an injection under the skin, in children and young adu…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can a new drug trio overcome venetoclax resistance in leukemia?
Disease control By invitation onlyResearchers are testing whether a combination of homoharringtonine, lisaftoclax, and azacitidine can help adults with acute myeloid leukemia (AML) whose disease stopped responding to venetoclax-based treatment. The trial plans to enroll 73 participants and give them the three dru…
Phase 2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Targeted drug TQB2102 takes aim at HER2-Low breast cancer
Disease control OngoingResearchers are testing an experimental antibody-drug conjugate called TQB2102 in people with recurrent or metastatic breast cancer that has low levels of the HER2 protein. The trial enrolls about 542 adults who have not yet received chemotherapy for their advanced disease. Parti…
Phase 3 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can immunotherapy before surgery shrink head and neck tumors?
Disease control OngoingResearchers are testing whether adding the immunotherapy drug toripalimab to standard chemotherapy (gemcitabine and cisplatin) before surgery can help patients with locally advanced head and neck squamous cell carcinoma. The trial enrolls about 20 adults whose tumors can be remov…
Phase 1 • Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Tailored Three-Drug combo targets Myeloma's toughest genetic weak spot
Disease control OngoingResearchers are testing whether a combination of daratumumab, pomalidomide and dexamethasone can help people whose multiple myeloma has come back and carries a genetic change called del(17p). This change, found in about 10% of patients at diagnosis, makes the cancer harder to tre…
Phase 2 • Sponsor: Fondazione EMN Italy Onlus • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can focused radiation replace surgery for inherited pancreatic tumors?
Disease control OngoingPeople with MEN1 syndrome inherit a high risk of developing multiple pancreatic neuroendocrine tumors. Surgery is the only curative option but causes major complications. Researchers are testing high-dose, high-precision MR-guided radiotherapy to see if it can shrink these tumors…
Sponsor: J.M. de Laat • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Sea sponge compound tested against bladder cancer in patients with poor kidney function
Disease control OngoingResearchers are studying eribulin mesylate, a chemotherapy drug, in people with urothelial cancer that has spread or cannot be removed by surgery, and who also have kidney problems. The trial has two parts: one to find the highest dose patients can tolerate, and another to see ho…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a daily pill help breast cancer that outsmarts two antibody drugs?
Disease control OngoingResearchers are reviewing medical records to see how well pyrotinib works and how safe it is in people with HER2-positive advanced breast cancer whose disease worsened after treatment with trastuzumab and pertuzumab. The study includes about 200 patients in China who received pyr…
Sponsor: Beijing 302 Hospital • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Triple attack on HER2-Positive stomach cancer: can chemo, targeted therapy and immunotherapy shrink tumors before surgery?
Disease control OngoingResearchers are testing whether combining FLOT chemotherapy, trastuzumab and toripalimab before and after surgery helps people with HER2-positive stomach or esophagogastric junction cancer. The trial enrolls about 30 adults with locally advanced, operable tumors. Participants rec…
Phase 2 • Sponsor: Yu jiren • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug takes aim at ovarian cancers that resist platinum chemotherapy
Disease control OngoingResearchers are testing an experimental drug called IBI354 in people with ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The trial compares IBI354 given alone with one of four standard chemotherapy drugs chosen by…
Phase 3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
A scanner in the operating room could show surgeons exactly where prostate cancer remains
Diagnosis OngoingSurgeons removing a prostate for cancer can struggle to tell cancerous tissue from healthy tissue, and cancer left at the edge of the removed gland is usually found only days later under a microscope. This pilot study at Geneva University Hospitals tests whether a PET/CT scanner …
Sponsor: University Hospital, Geneva • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Could MRI make CT scans obsolete for thymoma patients?
Diagnosis OngoingThis study compares MRI scans to standard CT scans for staging thymoma, a rare chest tumor. Researchers want to see if MRI can detect tumor spread just as well or better, without using radiation. Forty adults with newly diagnosed or recurrent thymoma will undergo both scans befor…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Self-sampling for cervical cancer screening could make testing easier and more accessible
Diagnosis OngoingThis study tests whether offering a self-sampling HPV test at a clinic increases the number of women who get screened for cervical cancer. Women who are due for screening can choose between a self-sampled test, a clinician-sampled test, or no screening. The study measures how man…
Sponsor: Milton S. Hershey Medical Center • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Contrast-Enhanced mammography: sharper images to catch hidden breast cancers?
Diagnosis OngoingThis study tests whether contrast-enhanced mammography (CEM) — a mammogram with an iodine dye injection — can find breast cancer more accurately than standard mammography. Researchers will compare CEM with other imaging methods in 100 women who have suspicious breast findings and…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
Blood thinner flush could boost tumor biopsy success
Diagnosis CancelledResearchers test whether flushing the biopsy needle with heparin, a blood thinner, helps collect more and better tissue from solid abdominal tumors during endoscopic ultrasound-guided fine needle biopsy. They also test whether using a microsieve to prepare the tissue improves the…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Light-Based probe aims to spot thyroid cancer faster
Diagnosis CancelledResearchers are testing a technique called Raman spectroscopy to see if it can accurately identify thyroid cancer in tissue samples. The study involves patients who are already having a routine thyroid biopsy for suspected cancer. After the biopsy, the removed tissue is examined …
Sponsor: Gloucestershire Hospitals NHS Foundation Trust • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
New PET tracer could sharpen sarcoma detection
Diagnosis OngoingThis early-phase trial tests a radioactive tracer called 68Ga-FAPI-46 to see where it collects in the body of people with sarcoma. Participants receive the tracer and undergo a PET/CT scan, which combines a detailed anatomical image (CT) with a functional image (PET) that highlig…
Early phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can a simple score spot hidden gallbladder cancer?
Diagnosis OngoingResearchers are studying whether they can predict which patients having routine gallbladder removal for gallstones or related problems might have unsuspected gallbladder cancer. They plan to collect data from up to 30,000 adults and use risk factors to build a scoring system. The…
Sponsor: University Hospital Plymouth NHS Trust • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Pee test could replace scope for bladder cancer checks
Diagnosis OngoingThis study is testing a simple urine test called CxBladder to see if it can accurately detect when bladder cancer comes back. Currently, patients need a camera inserted into the bladder (cystoscopy) for monitoring, which is uncomfortable and costly. The study will collect urine s…
Sponsor: Pacific Edge Limited • Aim: Diagnosis
Last updated Sep 19, 2026 00:00 UTC
-
Can MRI spot which prostate cancers are safe to watch?
Diagnosis By invitation onlyResearchers at Herlev Hospital are studying whether multiparametric MRI can help doctors decide which men with low-risk prostate cancer can safely stay on active surveillance instead of getting treatment. The trial enrolls 150 men with newly diagnosed low-risk prostate cancer who…
Sponsor: Herlev Hospital • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New MRI technique could help men with prostate cancer avoid unnecessary treatment
Diagnosis By invitation onlyThis study is testing whether a special type of MRI (multiparametric MRI) can better identify which men with low-risk prostate cancer can safely delay treatment. About 200 men already on active surveillance will receive the MRI, and if suspicious areas are found, they will get ad…
Sponsor: Herlev Hospital • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Pee test may spare thousands from painful bladder scopes
Diagnosis OngoingThis study is testing a new, non-invasive urine test called Cxbladder Triage-Plus to see if it can accurately detect bladder cancer in people who have microscopic blood in their urine. Currently, these patients often need a cystoscopy, an invasive procedure where a camera is inse…
Sponsor: Pacific Edge Limited • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
Tiny DNA fragments in blood could reveal how aggressive a pancreatic tumor will be
Diagnosis OngoingPancreatic neuroendocrine tumors behave unpredictably: some stay slow for years while others spread quickly, and doctors lack reliable tests to tell them apart before surgery. This study examines cell-free DNA, tiny genetic fragments shed by tumors into the bloodstream, from abou…
Sponsor: Massimo Falconi • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
New scan could spot childhood cancer more clearly
Diagnosis CancelledThis study tests whether a new type of PET scan (18F-MFBG) can detect neuroblastoma tumors as accurately as the current standard scan (123I-MIBG). About 84 children and adults with newly diagnosed, high-risk neuroblastoma will receive both scans to compare results. If the new sca…
Phase 2 • Sponsor: Children's Oncology Group • Aim: Diagnosis
Last updated Sep 18, 2026 00:00 UTC
-
AI reads scans to spot prostate cancer, spare unnecessary biopsies
Diagnosis By invitation onlyThis study aims to develop an artificial intelligence (AI) model that combines two advanced imaging techniques—multiparametric MRI and PSMA PET/CT—to more accurately diagnose prostate cancer. By analyzing data from up to 1,500 patients, the AI model is designed to identify clinic…
Sponsor: Xiangya Hospital of Central South University • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
New MRI technique could sharpen prostate cancer staging
Diagnosis OngoingThis study looks at whether a special type of MRI, called multiparametric MRI, can more accurately determine the stage of prostate cancer in people who are newly diagnosed and planning surgery. The goal is to see if this imaging method helps doctors find aggressive cancers and ma…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
Can a special PET scan change the course of prostate cancer?
Diagnosis OngoingResearchers are running a registry to see how a PET scan using PYLARIFY (piflufolastat F18) affects real-world care for men with prostate cancer. The study will follow 500 men for up to 5 years, collecting data every 6 months on their diagnosis, treatment, and outcomes. The goal …
Sponsor: Lantheus Medical Imaging • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
AI reads CT scans to spot liver cancer before It's too late
Diagnosis OngoingThis study tests an AI tool called LEAF that helps doctors analyze CT scans of the abdomen to find liver cancer early. Researchers will use scans from 10,000 patients with confirmed liver tumors to train the AI to better detect cancer. The goal is to improve early screening and g…
Sponsor: Zhejiang University • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
New MRI dye could spot prostate cancer more clearly
Diagnosis CancelledThis study is testing whether a special MRI contrast called hyperpolarized pyruvate can help doctors see prostate tumors more clearly than standard MRI. About 130 men with prostate cancer will receive the contrast before imaging. The goal is to improve cancer detection and diagno…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
AI-Powered Low-Dose CT could spare cancer patients unnecessary radiation
Diagnosis OngoingThis study tests whether a low-radiation CT scan, enhanced with artificial intelligence software, can detect liver tumors as accurately as a standard CT scan. About 146 adults with colorectal cancer and known liver metastases will receive both scans. The goal is to see if the low…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
PET scans may guide breast cancer treatment before surgery
Diagnosis OngoingThis phase 2 trial tests whether a special PET/CT scan using a radioactive tracer (FDG) can predict how well HER2-positive breast cancer responds to standard chemotherapy before surgery. About 235 patients with stage II-III HER2+ breast cancer will get the scan early in treatment…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Glow-in-the-Dark mouth scans could catch cancer early
Diagnosis OngoingThis study tests whether special lights and cameras can help find early signs of mouth cancer in people at high risk. About 338 participants with precancerous spots or conditions like Fanconi anemia will have their mouths examined with fluorescence imaging, which makes abnormal c…
Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
New radioactive tracer could spot hidden tumors
Diagnosis OngoingThis early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …
Phase 1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Finger prick vs. needle: can a drop of blood replace the lab draw?
Diagnosis CancelledResearchers are testing whether a finger-prick blood testing device, the Entia Liberty System, gives accurate results compared with standard laboratory blood tests. Participants are adults receiving systemic anti-cancer therapy who already need routine full blood count tests. The…
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Can cancer patients test their own blood at home?
Diagnosis CancelledResearchers are studying whether the Entia Liberty, a home blood testing device, is easy and safe for cancer patients to use on their own. Participants are adults receiving systemic anti-cancer therapy who can read English and give consent. The trial measures how well patients op…
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Prostate cancer blood test targets particles shed by tumors
Diagnosis PausedResearchers are studying whether a blood test can detect prostate cancer by finding prostasomes, tiny particles that prostate cancer cells release into the blood. The trial enrolls men with elevated PSA levels or diagnosed prostate cancer who have not yet received treatment. The …
Sponsor: Hackensack Meridian Health • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
New blood panel aims to catch liver cancer before it spreads
Diagnosis OngoingResearchers are testing a blood test panel called Glycotest HCC to see if it detects early-stage liver cancer better than the standard alpha-fetoprotein (AFP) test. The study includes 766 people with cirrhosis, some of whom have early liver cancer and some who do not. Participant…
Sponsor: Glycotest, Inc. • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Sharper scans could streamline radiation planning
Diagnosis OngoingRadiation teams use cone beam CT scans to line up patients with the treatment beam, but standard images are not clear enough to map tumors or calculate doses. This study tests whether a new imaging system called HyperSight, built into the TrueBeam radiotherapy machine, can produc…
Sponsor: Varian, a Siemens Healthineers Company • Aim: Diagnosis
Last updated Sep 11, 2026 00:00 UTC
-
Can a smaller dose of a white blood cell booster protect cancer patients just as well?
Prevention By invitation onlyResearchers are studying whether a lower 3mg dose of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can prevent febrile neutropenia, a serious drop in infection-fighting white blood cells, in cancer patients after chemotherapy. The standard 6mg do…
Sponsor: Zhejiang Provincial People's Hospital • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Aspirin shows promise in blocking ovarian cancer for High-Risk women
Prevention OngoingThis study tests whether taking aspirin can prevent ovarian cancer in women with BRCA1 or BRCA2 gene mutations, who are at high risk. About 117 participants will take either aspirin or a placebo daily for up to 2 years before their scheduled risk-reducing surgery. Researchers wil…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
New hope: natural compound may stop chemo nerve pain
Prevention OngoingThis study tests a natural substance called GM1 to see if it can prevent nerve damage (pain, numbness, tingling) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo alongside their chemo. T…
Phase 2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can diet and exercise programs cut cancer risk? new study tests lifestyle changes
Prevention OngoingThis study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…
Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
A new strategy to prevent cervical cancer: community follow-up for HPV shots
Prevention OngoingThis trial tests whether proactive follow-up by community health workers can increase HPV vaccination coverage among adolescent girls in Mali and Côte d'Ivoire. Researchers compare girls who receive home visits and digital reminders to those getting standard outreach. The goal is…
Sponsor: Arsène Brunelle Sandie • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Turmeric compound tested to stop stomach cancer before it starts
Prevention OngoingThis study tests whether curcumin, a compound found in turmeric, can prevent stomach cancer in people with chronic atrophic gastritis or gastric intestinal metaplasia. About 50 participants will receive either curcumin or a placebo for a period, and researchers will measure chang…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Can a vaccine stop oral HPV in men with HIV?
Prevention OngoingThis study tests whether the nine-valent HPV vaccine can prevent long-lasting oral HPV infections in men who have HIV. About 700 men will receive either the vaccine or a placebo. The goal is to see if the vaccine reduces new persistent infections with HPV types linked to throat c…
Phase 3 • Sponsor: Weill Medical College of Cornell University • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Can a vaccine stop GI cancers from returning?
Prevention PausedResearchers are testing an experimental vaccine called Ad5.F35-hGCC-PADRE in adults who have had surgery and standard treatment for gastrointestinal cancers, including pancreatic, colorectal, esophageal, gastric, and small bowel adenocarcinomas. The trial aims to find a safe dose…
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Gene test may reveal which early lung cancers need chemo after surgery
Prevention OngoingResearchers are testing whether a 14-gene test can identify people with early-stage non-squamous non-small cell lung cancer who are at higher risk of the cancer returning after surgery. Patients whose tumors are completely removed and who test as intermediate or high risk are ran…
Sponsor: Razor Genomics • Aim: Prevention
Last updated Sep 13, 2026 00:00 UTC
-
Can electronic alerts and patient teaching stop deadly clots after cancer surgery?
Prevention OngoingBlood clots after major cancer surgery are common and dangerous, but patients often leave the hospital without medicine that lowers that risk. Researchers at the Medical University of South Carolina are testing whether educating surgeons and adding an electronic alert in the medi…
Sponsor: Medical University of South Carolina • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
Phone therapy shows promise for depression in ovarian cancer patients
Symptom relief OngoingThis study looks at whether weekly phone counseling can help identify and treat depression in women with ovarian, peritoneal, or fallopian tube cancer. About 409 participants will either receive phone counseling or standard care with resource lists. The goal is to see which appro…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Home workouts may help endometrial cancer survivors shed pounds
Symptom relief OngoingThis study tests whether a home-based weight loss program, with or without resistance training, is practical for endometrial cancer survivors. Fifteen participants will follow a program using a workbook, fitness tracker, and coaching calls. The goal is to see if they can lose wei…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Could two weeks of radiation be as good as six for this brain cancer?
Symptom relief OngoingThis study is for people with a rare and aggressive brain tumor called diffuse midline glioma. Instead of the usual six weeks of daily radiation, researchers are testing a shorter course of just two weeks. The goal is to see if the shorter treatment works just as well at controll…
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Exercise and diet may ease fatigue in CLL patients
Symptom relief OngoingThis study looks at whether exercise and weight management can help reduce fatigue in people who have had chronic lymphocytic leukemia (CLL). About 30 adults aged 18-85 with CLL will take part. Participants will be randomly assigned to start the program right away or after a wait…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Massage may ease chemo nerve damage
Symptom relief OngoingThis study looks at whether massage therapy can reduce nerve problems like pain, numbness, and tingling caused by chemotherapy in people with breast or digestive system cancers. About 90 participants will receive massage sessions to see if it improves symptoms and quality of life…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
One shot of radiation may ease cancer symptoms as well as multiple sessions
Symptom relief OngoingThis study compares a single session of palliative radiation therapy to the standard multiple sessions for people with gynecologic cancers that have spread. The goal is to see if one treatment can improve symptoms like pain and bleeding and boost quality of life just as well. Abo…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can a video-based therapy tame tough behaviors in kids with rare genetic disorders?
Symptom relief OngoingThis study tests a virtual behavioral therapy (Functional Behavioral Training) for children aged 2-12 with genetic syndromes like Fragile X, Angelman, or Rett syndrome who have challenging behaviors. The therapy teaches parents how to identify what triggers problem behaviors and …
Sponsor: Rush University Medical Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Mind over scalpel: Self-Hypnosis may ease Post-Surgery pain for cancer patients
Symptom relief OngoingThis study looks at whether listening to a self-hypnosis audio before surgery can help women with gynecologic cancer feel less pain and recover faster. About 152 patients having surgery for cancers of the female reproductive system will be randomly assigned to either usual care o…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can surgeons spare nerves and still cure colon cancer?
Symptom relief OngoingDoctors remove right or left colon cancer along with nearby lymph nodes, but the deep nerves that control the gut often get damaged. That damage can leave patients with lasting diarrhea, bowel spasms, or slow bowel movements. This trial compares standard surgery with a laparoscop…
Sponsor: Fudan University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Could a 4-Hour infusion replace 20 hours for neuroblastoma kids?
Symptom relief OngoingThis study tests if giving the drug dinutuximab over 4 hours or less is safe and practical for children with high-risk neuroblastoma. Currently, standard infusions take 10-20 hours and require a hospital stay. The goal is to see if a shorter infusion can be used in an outpatient …
Phase 2 • Sponsor: Children's Hospital Los Angeles • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can mindfulness ease cancer stress for latino families?
Symptom relief OngoingThis study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
A bag that holds the small intestine could change colon surgery
Symptom relief By invitation onlyDuring laparoscopic surgery on the rectum or lower sigmoid colon, the small intestine can slip into the operating area and block the surgeon's view. This trial tests a disposable isolation device that holds the small intestine away from the surgical site. Researchers compare the …
Sponsor: Beijing Friendship Hospital • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Mindfulness program aims to ease lung cancer breathlessness
Symptom relief OngoingThis study tests a 6-week mindfulness-based program for lung cancer patients struggling with breathlessness, cough, and fatigue. The program combines mindful breathing, relaxation, cough control, acupressure, and light exercise. Researchers will check if it's practical and liked …
Sponsor: The Hong Kong Polytechnic University • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New study tracks how well thyroid ablation eases symptoms
Symptom relief By invitation onlyThis Mayo Clinic study tracks 300 patients undergoing radiofrequency ablation for symptomatic thyroid nodules. Researchers use a simple questionnaire to measure changes in symptoms like discomfort or swallowing issues before and after the procedure. The goal is to better understa…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Can a website help liver cancer patients care for themselves during chemoembolization?
Symptom relief OngoingResearchers are testing whether an enhanced web-based health education program helps people with hepatocellular carcinoma (liver cancer) improve their self-care and quality of life while undergoing transarterial chemoembolization (TACE). The trial enrolls 252 adults scheduled for…
Sponsor: University Medical Center Ho Chi Minh City (UMC) • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Legal aid may ease burden for cancer caregivers
Symptom relief OngoingThis pilot study offers free legal services to caregivers and patients dealing with advanced colorectal cancer. The goal is to see if early legal support can reduce financial and emotional stress. Twenty patient-caregiver pairs will receive personalized legal help from a nonprofi…
Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New shot aims to quiet chemo nerve pain
Symptom relief OngoingThis study tests an injected drug called Halneuron to see if it can safely reduce nerve pain caused by chemotherapy. About 240 adults who have nerve pain from platinum or taxane chemo will receive either Halneuron or a placebo shot. The goal is to measure pain relief, sleep, fati…
Phase 2 • Sponsor: Dogwood Therapeutics Inc. • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New meditation program aims to ease cancer symptoms in black patients
Symptom relief OngoingThis study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Could a social media app help heal the emotional scars of cancer?
Symptom relief By invitation onlyThis trial tests whether a program designed to boost social connections can improve the social and emotional well-being of young adults who had cancer. Participants, aged 22-39 and diagnosed between 15-39, will receive a video and planning tools to encourage more in-person intera…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
One-Day liver cancer treatment shows promise in early trial
Symptom relief OngoingThis early-phase study tests whether a liver cancer treatment called Y90 radioembolization can be safely done in a single session instead of the usual two-day process. The treatment uses tiny radioactive beads injected into the liver's blood supply to block tumor growth. Research…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief OngoingThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Sponsor: University of Florida • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Needle in the spine: new hope for cancer pain?
Symptom relief OngoingThis study tests a procedure called cordotomy, where a needle is guided into the spinal cord to block pain signals. It's for people with advanced cancer who have severe pain on one side of the body below the shoulder. The goal is to see if it reduces pain better than a fake proce…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New radiation approach may spare thinking skills in brain cancer patients
Symptom relief OngoingThis study compares two radiation treatments for people whose non-melanoma cancer has spread to the brain with 4 to 15 tumors. One method, stereotactic radiosurgery, delivers a high dose only to the tumors, while the other treats the whole brain. The goal is to see which better c…
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Mindfulness may lift mood in older black breast cancer survivors
Symptom relief OngoingThis study aims to develop and test a shortened version of Mindfulness-Based Cognitive Therapy (MBCT) to improve mood in older African American/Black women who have had breast cancer and now have mild to moderate depression. About 23 participants will attend group sessions and re…
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New drug hopes to boost Radiation's punch against tough gut cancers
Symptom relief OngoingThis early-phase study tests an oral drug called ropidoxuridine (IPdR) in people with advanced gastrointestinal cancers that cannot be cured. The goal is to find the safest dose and see if it can make radiation therapy more effective at shrinking tumors. Nineteen participants wit…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Picture this: simple photo tool may ease anxiety for breast cancer patients
Symptom relief OngoingThis study tests whether adding a photo guide to standard counseling helps reduce anxiety and depression in women with early-stage breast cancer who are about to start radiation therapy. About 62 participants will either receive standard verbal counseling alone or with a pictoria…
Sponsor: OHSU Knight Cancer Institute • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can an epidural pump beat IV painkillers after liver surgery?
Symptom relief OngoingThis trial compares two ways to control pain after open liver surgery: an epidural pump that delivers pain medicine near the spine, versus a standard IV pump. About 230 adults having elective open liver resection will be randomly assigned to one method. The goal is to see which a…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Could a stick help you quit smoking? new study tests it in lung cancer patients
Symptom relief OngoingThis study tests a new tool called the Buckeye Quit Stick to help smokers with lung cancer quit. The stick replaces the hand-to-mouth habit of smoking without using medicine. About 30 adults will try it for 6 months to see if it helps them stay smoke-free.
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Nurses bring therapy to homebound cancer patients
Symptom relief OngoingThis study trains home-care nurses to deliver a short, meaning-centered psychotherapy to cancer patients who are homebound. The goal is to see if this approach can reduce psychological distress and improve quality of life. The trial involves 81 participants and focuses on trainin…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Pre-surgery fitness program tested in elderly cancer patients
Symptom relief OngoingThis study tests a program of exercise, protein drinks, and mind-body activities like yoga for people aged 65 and older with advanced ovarian or pancreatic cancer. The goal is to see if patients can stick with the program while on chemotherapy before surgery. The study is small, …
Phase 1/2 • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
AI reads your social media to boost breast cancer mental health
Symptom relief OngoingThis study tests whether an AI system that analyzes social media posts can improve quality of life for breast cancer patients. 440 women will either use the AI system plus usual care or just usual care for 6 months. The goal is to see if personalized emotional support reduces anx…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Mind over lymphoma: meditation trial aims to ease young Patients' distress
Symptom relief OngoingThis study tests whether a meditation-based mind-body program can improve quality of life for adolescents and young adults (ages 18-39) recently diagnosed with lymphoma. Participants practice guided meditation and mindfulness techniques to help lower distress, anxiety, and depres…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
New gel shields bowel during prostate radiation – could cut side effects
Symptom relief OngoingThis trial tests a biodegradable gel called SpaceOAR Vue that is injected between the prostate and rectum before radiation therapy. The gel temporarily pushes the rectum away to reduce radiation damage. About 500 men with intermediate-risk prostate cancer will be randomly assigne…
Sponsor: Boston Scientific Corporation • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Spine radiation showdown: one big blast or three small doses?
Symptom relief OngoingThis study tests whether a single large dose of spine radiosurgery works better than three smaller doses for people whose spinal tumors have come back after previous radiation. About 80 adults with solid tumors that spread to the spine will be randomly assigned to one of the two …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Hypnosis may replace anesthesia for some breast cancer surgeries
Symptom relief OngoingThis study looks at whether hypnosis can help women with early-stage breast cancer relax during surgery, possibly reducing the need for general anesthesia. About 50 women will try hypnosedation, a technique that uses words and images to keep them calm and awake while numb. The go…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can a common antipsychotic combo calm delirium in dying cancer patients?
Symptom relief OngoingThis study tests whether giving haloperidol alone or with chlorpromazine can safely calm severe agitation and confusion (delirium) in 70 advanced cancer patients in a palliative care unit. The main goal is to see if the drugs improve sedation scores within 24 hours. It is a phase…
Phase 2/3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Mouth device aims to keep Sore-Relief rinses where They're needed
Symptom relief CancelledResearchers are testing a new medical device called Bocaliner in people who have painful mouth sores caused by chemotherapy or radiation. The device is held in the mouth after using medicated mouthwashes, gels, or rinses, with the goal of keeping those treatments in contact with …
Early phase 1 • Sponsor: E2Bio Life Sciences, LLC • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can starting anemia drug sooner keep MDS patients off transfusions?
Symptom relief OngoingResearchers are testing whether starting epoetin alfa early, as soon as anemia appears, works better than waiting until a person needs blood transfusions. The trial enrolls adults with lower risk myelodysplastic syndromes (MDS) who have mild anemia and are not yet dependent on re…
Phase 3 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a virtual stress program help working spouses care for cancer patients without burning out?
Symptom relief OngoingResearchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…
Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can an online program ease the burden on cancer caregivers?
Symptom relief OngoingResearchers at Uppsala University are testing whether an internet-based support program called Carer eSupport helps informal caregivers of head and neck cancer patients feel more prepared for their role. The trial enrolls 110 caregivers whose relatives are about to start or have …
Sponsor: Uppsala University • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can art therapy tune the body and mind to ease insomnia after breast cancer?
Symptom relief OngoingResearchers are testing a three-part art therapy program for women aged 45 and younger who have had breast cancer surgery. The program combines body, voice, and mind exercises. The trial measures changes in insomnia severity and overall physical, mental, and social wellbeing. It …
Sponsor: Keda Yu • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a Nine-Week group program help blood cancer patients grow through trauma?
Symptom relief OngoingResearchers in Greece are testing a nine-session group program called TRANSFORM for people who have finished treatment for blood cancers such as leukemia, lymphoma, and myeloma. The program combines teaching, reflection, coping exercises, and mindfulness to see whether it can spa…
Sponsor: University of West Attica • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can an online program ease depression in young colorectal cancer survivors?
Symptom relief OngoingResearchers test an 8-week online precision nursing education program for young colorectal cancer survivors. The program includes Qigong exercise and mindfulness training delivered through an e-flipped classroom model. The study measures changes in depression symptoms and mindful…
Sponsor: Fooyin University • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can a Five-Session program help young cancer patients keep their friendships?
Symptom relief OngoingResearchers are testing a five-session program called PRISM-SN for people aged 12 to 25 who were recently diagnosed with cancer and are receiving chemotherapy or radiation. The program teaches skills for managing stress, setting goals, reframing negative thoughts, finding meaning…
Sponsor: Seattle Children's Hospital • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
New hope for myeloma patients: switching to ixazomib after failed treatments?
Knowledge-focused OngoingThis study follows 72 adults with multiple myeloma who switch from a bortezomib- or carfilzomib-based treatment to an ixazomib-based regimen. Researchers are tracking side effects and how long patients go without the disease getting worse. The goal is to see if this switch is a g…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can a Pre-Surgery diet change help prostate cancer patients?
Knowledge-focused OngoingThis study looks at whether men with intermediate-risk prostate cancer can follow a Mediterranean diet before their surgery to remove the prostate. The goal is to see if this diet is practical and well-tolerated. Twelve participants will eat specially prepared meals and then unde…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
NIH opens screening study to find candidates for blood disorder research
Knowledge-focused By invitation onlyThis study screens up to 10,000 people with blood disorders or healthy volunteers to see if they can safely join other active research studies at the National Heart, Lung, and Blood Institute. Participants undergo clinical, imaging, and lab tests. If no suitable study is availabl…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
10-Year NF1 study aims to unlock secrets of rare genetic disorder
Knowledge-focused OngoingThis natural history study follows 259 children, adolescents, and adults with Neurofibromatosis Type 1 (NF1) for up to 10 years. Researchers will track tumor growth, monitor quality of life, and perform genetic testing to better understand how the disease changes over time. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Blood tests could reveal secrets of rectal cancer
Knowledge-focused OngoingThis study looks at tiny pieces of cancer cells or DNA floating in the blood of people with rectal cancer. Researchers want to see if these markers can help predict how the tumor responds to standard treatment. About 341 participants, including healthy volunteers, will provide bl…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gut bacteria may hold clues to why some cancer treatments work better
Knowledge-focused PausedResearchers are building a large bank of blood and stool samples from people with advanced lung, breast, colorectal, and pancreatic cancers, plus healthy volunteers. The goal is to learn whether the mix of bacteria in a person's gut can predict how well cancer treatment works and…
Sponsor: Persephone Biosciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Massive data collection aims to spark breakthroughs in blood disorders
Knowledge-focused By invitation onlyThis study gathers medical information from up to 10,000 people with blood or heart conditions, as well as stem cell donors, treated at the National Institutes of Health. Researchers will review participants' medical records, test results, and treatments to build a database for g…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can a simple text reminder help catch lung cancer early?
Knowledge-focused OngoingThis study tests whether reminder messages can encourage people aged 40-80 who smoke or have smoked to get screened for lung cancer. Researchers will ask about 133 participants how acceptable they find these reminders. The goal is to see if this simple approach could help more pe…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Education boosts genetic testing in black prostate cancer patients
Knowledge-focused OngoingThis pilot study aims to see if a brief educational session can increase the number of Black men with aggressive prostate cancer who complete genetic testing. Researchers will enroll 50 men who identify as Black or multiracial and have high-risk prostate cancer. Participants will…
Sponsor: Henry Ford Health System • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Melanoma survivors: new study tracks immunotherapy side effects
Knowledge-focused OngoingThis study follows 126 melanoma survivors who are receiving immunotherapy after surgery. Researchers will track side effects and quality of life for up to 24 months. They will also collect blood samples to look for markers that might predict who gets side effects. The goal is to …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gene test may guide breast cancer therapy choices
Knowledge-focused OngoingThis study looks at whether a genetic test on tumor samples can predict how well HER2-negative breast cancer will respond to standard treatments like chemotherapy or hormone therapy. About 1,100 people with stage I-III breast cancer are taking part. The goal is to see if this tes…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can a smartphone app give prostate cancer patients more control?
Knowledge-focused By invitation onlyResearchers are studying whether a mobile health app called myAria helps adult prostate cancer patients track symptoms, share health data, and feel more empowered during treatment. Participants use the app to log side effects and well-being, complete questionnaires, and view a no…
Sponsor: Constantinos Zamboglou • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Childhood farm life under the microscope: could pesticides raise cancer risk?
Knowledge-focused By invitation onlyThis study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gut microbes may hold key to why cancer immunotherapy works for some
Knowledge-focused By invitation onlyResearchers are building a bank of blood, urine, and stool samples from 100 adults with non-small-cell lung or colorectal cancer who are receiving checkpoint inhibitor immunotherapy. Over 12 months, participants provide five samples of each type. The goal is to study how the body…
Sponsor: Persephone Biosciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Radiation for 6+ brain tumors: how does it affect memory?
Knowledge-focused OngoingThis study looks at how precise radiation (stereotactic radiosurgery) affects memory and thinking in people with 6 or more brain tumors that have spread from other cancers. About 80 adults will take part to find the safest radiation dose and measure any decline in memory over 4 m…
Phase 1/2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Biopsy vs. surgery: could some breast cancer patients avoid the knife?
Knowledge-focused OngoingThis study tests whether a less invasive ultrasound-guided biopsy can accurately tell if breast cancer has been completely wiped out by chemotherapy, compared to the standard method of checking during surgery. About 43 women with aggressive breast cancer types (triple negative or…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New program aims to lift mood and boost treatment adherence in head and neck cancer
Knowledge-focused OngoingThis study tests a new program designed to help head and neck cancer patients who feel depressed. The goal is to see if the program is practical and liked by patients, and if it can improve their mood and help them follow through with swallowing exercises and dental care. About 1…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New PET scan tracks immune response in melanoma patients
Knowledge-focused OngoingThis early-phase trial tested a special PET/CT imaging agent, Zirconium Zr 89 Crefmirlimab Berdoxam, to see if it can measure immune activity in tumors of patients with advanced melanoma. Six adults on immunotherapy plus hydroxychloroquine received scans before and after starting…
Early phase 1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists hunt for clues to drug resistance in advanced breast cancer
Knowledge-focused OngoingThis study follows 25 women with advanced breast cancer to understand why the drug palbociclib stops working over time. Researchers collect blood and tumor samples before and after the cancer progresses to look for genetic and chemical changes. The goal is not to treat the diseas…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
MD anderson study seeks to improve care for asian cancer patients
Knowledge-focused OngoingThis study aims to understand what helps or hinders a positive experience for Asian patients being treated for cancer at MD Anderson. Researchers will survey former patients and healthcare providers to identify key factors. The goal is to use these insights to improve care and su…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Real-World data reveals how lung cancer drug lorlatinib performs outside the lab
Knowledge-focused OngoingThis study looks at how patients with ALK-positive advanced non-small cell lung cancer respond to the drug lorlatinib when used as their first treatment in real-world settings. Researchers will analyze data from 200 patients in a U.S. database to see how long they stay on the dru…
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Personalized risk reports may boost lung cancer screening and smoking cessation
Knowledge-focused By invitation onlyThis study tests whether giving smokers and former smokers a personalized risk report (based on clinical and genetic factors) helps doctors order lung cancer screening and helps patients follow through. About 915 participants will be randomly assigned to usual care or one of two …
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Real-World melanoma care under the microscope
Knowledge-focused OngoingResearchers are studying how advanced and metastatic melanoma is diagnosed and treated in everyday Spanish clinics. The study follows about 400 adults with stage III, metastatic, or unresectable melanoma from their first diagnosis. No experimental treatment is given; instead, the…
Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Robotic surgery showdown: single port vs. multi port for prostate cancer
Knowledge-focused OngoingThis study looks back at the records of 625 men who had robotic prostate surgery for localized prostate cancer. It compares a newer single-port method with the standard multi-port approach to see which leads to fewer complications and better urinary control. The goal is to gather…
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Could a frailty score predict which older cancer patients survive intensive care?
Knowledge-focused OngoingOlder adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Can skin strength predict implant success? new study investigates
Knowledge-focused OngoingThis study looks at skin and soft tissue removed during breast implant surgery after mastectomy. Researchers want to see if the physical properties of the tissue can help predict complications like implant loss. The goal is to better understand risks and improve surgical outcomes…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Smartwatch study aims to track cancer fatigue
Knowledge-focused OngoingThis pilot study is testing whether wearable activity trackers, like fitness watches, can help monitor fatigue in people with pancreatic or breast cancer who are undergoing treatment. Researchers want to see if patients will use the device daily and find it easy to use. The study…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive NCI study tracks thousands of cancer patients receiving standard care
Knowledge-focused By invitation onlyThis study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive farm study tracks Pesticide-Cancer links for decades
Knowledge-focused OngoingThis study follows nearly 90,000 farmers, their spouses, and pest control workers in Iowa and North Carolina over many years. Researchers track their exposure to pesticides and other farm chemicals, then monitor who develops cancer or other diseases. The goal is to identify which…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Real-World data sought on prostate cancer combo therapy
Knowledge-focused OngoingThis study watches how men with a certain advanced prostate cancer (mCRPC) do when taking the drugs olaparib and abiraterone in everyday medical practice. It will track about 250 patients for up to 2 years to see how long they stay on treatment and what happens next. The goal is …
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Why COVID-19 hits blood cancer patients harder: scientists map the immune clues
Knowledge-focused OngoingResearchers at Peking University First Hospital are studying how the immune system responds to SARS-CoV-2 infection in people who have blood cancers compared with people who have no underlying diseases. The observational study enrolls 60 participants and collects clinical details…
Sponsor: Peking University First Hospital • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Late-Night snacks and booze: a recipe for colon cancer?
Knowledge-focused OngoingThis study looks at how Western habits—like drinking alcohol and eating late—might raise the risk of colorectal cancer. Twelve adults who have had colon polyps in the past will try four different weekly routines, including eating at normal times or late, with or without alcohol. …
Sponsor: Rush University Medical Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Gene therapy patients monitored for 15 years to spot hidden side effects
Knowledge-focused By invitation onlyThis study follows up to 1,000 adults who previously received gene therapy in a National Cancer Institute study. Researchers will contact participants yearly for up to 15 years to check for any long-term side effects, such as new cancers or nerve problems. No new treatments are g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a phone app help childhood cancer survivors keep track of their health?
Knowledge-focused OngoingResearchers at the University of California, San Francisco are testing a mobile app built for survivors of childhood cancer and their caregivers. The app shows each person their treatment history and follow-up recommendations, and sends messages to help them learn about their dia…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New catheter aims to sharpen liver cancer radiation targeting
Knowledge-focused OngoingThis study tests whether a special catheter (TriNav) helps deliver radiation more accurately to liver tumors. About 19 adults with liver cancer that cannot be removed by surgery will receive a test dose followed by the actual treatment. The goal is to see if the two doses match b…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive cancer screening trial aims to cut deaths
Knowledge-focused OngoingThis study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
AI-Powered scans could speed up lung cancer radiation treatment
Knowledge-focused OngoingThis study looks at whether new AI tools can make adaptive radiotherapy—adjusting radiation plans during treatment—faster and easier for people with advanced lung cancer. Researchers will measure how long each step takes and compare plan quality using standard CT scans versus dai…
Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to boost genetic testing in cancer families
Knowledge-focused OngoingThis study looks at whether a website and a genetic family navigator can help more relatives of people with hereditary cancer get genetic testing. About 205 participants will use the online hub and work with a navigator to learn about their cancer risk. The goal is to see if this…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists hunt for hidden genes behind family blood cancer clusters
Knowledge-focused OngoingThis long-term study looks at people and families with a higher chance of developing blood or lymph node cancers like leukemia or lymphoma. Researchers collect medical histories, genetic samples, and sometimes perform exams to find inherited genes or environmental triggers. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can doctors safely watch small thyroid cancers instead of removing them?
Knowledge-focused OngoingResearchers at the University of Aarhus are studying whether people with a single thyroid cancer smaller than 2 cm can safely delay surgery and instead have the tumor monitored with ultrasound for five years. The study enrolls 90 adults aged 30 and older whose biopsy shows cancer…
Sponsor: University of Aarhus • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
When cancer blocks the airway, doctors lack a playbook. experts aim to write one.
Knowledge-focused By invitation onlyTumours in the head, neck, or chest can narrow or distort the airway, and standard difficult-airway guidelines offer little cancer-specific advice. This study asks an international panel of anaesthesiologists, intensive care doctors, lung specialists, head and neck surgeons, and …
Sponsor: Onco Critical Care Society • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New study aims to predict cancer return in Low-Risk patients
Knowledge-focused OngoingThis study looks at whether molecular testing and lymph node mapping can help predict if low-risk endometrial cancer will return after surgery. About 518 patients with early-stage, low-grade cancer will be followed for two years. The goal is to improve follow-up care by identifyi…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Blood cell collection could open door to CAR T-Cell therapy for leukemia and lymphoma patients
Knowledge-focused By invitation onlyThis study collects white blood cells from 120 people aged 3 to 65 with leukemia or lymphoma that hasn't been cured by standard treatments. The cells are gathered through a procedure called leukapheresis, then processed and frozen for future use in CAR T-cell therapy. The goal is…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists track families to uncover Cancer's hidden causes
Knowledge-focused OngoingThis study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Rare bone cancer study hunts for hidden genetic triggers
Knowledge-focused OngoingThis study aims to find genetic changes that may cause sporadic chordoma, a rare bone cancer. Researchers will collect saliva and medical records from 188 patients across the U.S. and Canada who are the only ones in their family with chordoma. No treatment is given; the goal is t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused By invitation onlyThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a genetic test and MRI team up to improve prostate cancer treatment choices?
Knowledge-focused OngoingThis study looks at whether combining a genetic test called the Genomic Prostate Score (GPS) with MRI scans can help doctors better choose men with prostate cancer for focal therapy, which treats only the cancerous part of the prostate. Researchers will analyze data and tissue sa…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New scan may predict chemo success in breast cancer patients
Knowledge-focused OngoingThis study looks at whether a special type of breast scan, called molecular breast imaging, can help doctors predict how well chemotherapy is working in women with invasive breast cancer. About 96 women will get the scan before, during, and after treatment. The goal is to see if …
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can your social life and genes predict cancer survivor health?
Knowledge-focused OngoingThis study examines how social and genetic factors influence long-term health in 2000 adolescent and young adult survivors of Hodgkin or non-Hodgkin lymphoma. Researchers will collect blood samples and health information to identify risks for disease recurrence, other illnesses, …
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can a simple MRI spot early success in brain cancer treatment?
Knowledge-focused OngoingThis study tests whether a special MRI scan, called DSC-MRI, can measure blood flow changes in brain tumors to predict if the drug bevacizumab is working early in treatment. Researchers will scan 146 patients with recurrent glioblastoma before and two weeks after starting the dru…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New brain scan may predict chemo brain in young leukemia patients
Knowledge-focused PausedThis study tests a quick, non-invasive brain scan called Magnetic Resonance Fingerprinting (MRF) in children and young adults with acute leukemia. The goal is to see if the scan can detect early brain changes caused by chemotherapy. Participants also take a fun, game-like memory …
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Fresh food for all: study tests Half-Price produce boxes to fight cancer risk
Knowledge-focused PausedThis study looks at whether delivering half-price produce boxes, with or without nutrition education, can help low-income families eat better and feel more food secure. Researchers will enroll 50 adults in Western New York who struggle to afford healthy food. The goal is to see i…
Sponsor: Roswell Park Cancer Institute • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New study hopes to outsmart pancreatic cancer by gathering clues
Knowledge-focused OngoingThis study collects health information and test results from 317 people at high risk for pancreatic cancer, including those with cysts, genetic syndromes, or other risk factors. Researchers aim to build a database to find better ways to detect the disease early or prevent it. No …
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Community cancer Centers' testing practices under review
Knowledge-focused CancelledThis study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Apple watch could predict brain tumor complications
Knowledge-focused PausedThis study explores whether an Apple Watch can track walking, heart rate, breathing, and sleep in people with glioblastoma, a serious brain cancer. The goal is to see if the watch can detect symptom changes before they become serious, like seizures or blood clots. Twenty-five pat…
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Do chemicals in your shampoo affect breast cancer? new study investigates
Knowledge-focused OngoingThis study looks at what breast cancer survivors and their family members know about chemicals in personal care products that might affect hormones. Researchers also want to see if there is a link between excess weight and these chemicals. About 30 people from the Acres Home comm…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can group classes boost cancer prevention in High-Risk women?
Knowledge-focused OngoingThis study tests whether group education sessions can help medically underserved women and racial/ethnic minorities with BRCA 1 or 2 mutations follow recommended cancer surveillance and risk-reducing procedures. Thirty participants will attend 90-minute group classes via Zoom. Th…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can a simple arm measurement help prevent lymphedema pain?
Knowledge-focused OngoingThis study asks breast cancer patients about their thoughts on screening for lymphedema, a common side effect where the arm becomes swollen and painful after treatment. Researchers use a device called a perometer to measure arm size before and after surgery. The goal is to see if…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Kidney cancer surgery may raise risk of scrotal swelling, study suggests
Knowledge-focused OngoingThis study reviewed health records of 40,000 men in Ontario, Canada, to see if those who had kidney cancer surgery (nephrectomy) were more likely to develop a hydrocele—a fluid-filled sac in the scrotum. Researchers compared men who had laparoscopic or open surgery to similar men…
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Cancer surgery opioid risk under microscope
Knowledge-focused OngoingThis study tracks 125 head and neck cancer patients after surgery to see how many end up using opioid painkillers long-term. Researchers will also look at factors like symptom burden and risk of opioid misuse. The goal is to better understand who is most at risk and why.
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New genome test aims to speed up leukemia diagnosis for kids
Knowledge-focused PausedThis study is testing whether a new genetic test called ChromoSeq can quickly and accurately classify leukemia in children and young adults. Researchers will collect blood or bone marrow samples from 60 participants at diagnosis and compare the test results to standard methods. T…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Researchers track rare thyroid cancer to uncover its secrets
Knowledge-focused OngoingThis study follows children and adults with medullary thyroid cancer (MTC), often linked to a genetic condition called MEN2. Researchers will track how the cancer grows and affects health over time using regular check-ups, blood tests, and imaging. No treatment is given, but part…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can we predict who recovers best from radical cancer surgery?
Knowledge-focused OngoingThis study follows women who have had pelvic exenteration—a surgery removing the lower colon, rectum, and bladder—for gynecologic cancers like cervical or endometrial cancer. Researchers want to see if factors like tumor size or surgery type affect complications, quality of life,…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
Can three numbers predict who will fail prostate cancer radiation?
Knowledge-focused OngoingResearchers are examining whether the Gleason score, prostate-specific antigen (PSA) level, and clinical stage can predict treatment failure, death, and quality of life in men who received radiation therapy for localized prostate cancer. The study reviews medical records and ques…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
AI could show breast cancer patients their future look after surgery
Knowledge-focused OngoingBreast cancer patients often face uncertainty about how surgery or radiation will affect their appearance. This trial compares a standard approach, where doctors explain outcomes verbally, with a new cloud-based platform that uses artificial intelligence to show patients simulate…
Sponsor: Fundacao Champalimaud • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC